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            Candida albicans is a major human fungal pathogen. A primary goal in studying 
C. albicans virulence is actually to find the ways to undermine it and prevent disease. The 
best drug targets are proteins or molecules that are not conserved in humans. For most 
antimicrobials against bacteria, fungi, or protozoans, the targets are not virulence factors, 
but rather enzymes that are important for basic growth or survival. It is not imperative 
that the target be required in all growth conditions, but rather just in the host.  An area of 
research that has shown promising potential for the discovery of new drug targets in 
several microbal pathogens is in phospholipid biosynthesis. In this dissertation, there are 
three projects that revolve around studying proteins that may be potential drug targets for 
C. albicans. 1) inositol biosynthesis was examined. It has been shown in the pathogens 
Mycobacterium tuberculosis and Trypanosoma brucei that de novo inositol biosynthesis 
is required for virulence or growth. Therefore, the enzyme required for de novo inositol 
synthesis was examined for a role in virulence. 2)  The phosphatidylserine (PS) synthase 
gene (CHO1) of S. cerevisiae is conserved in other fungi, and is not conserved in humans.  
Given that PS is an abundant phospholipid in yeasts, it was hypothesized that it would be 
important for virulence in the host. 3) Fungi carry homologs of a fungal-specific 
transcription factor, called Opi1p, that has been shown to be involved in regulating 
filamentous growth and phospholipid biosynthesis in S. cerevisiae. Its homolog was 
examined in C. albicans to determine if it regulated these phenotypes in this pathogen 
because filamentous growth is an important virulence factor. If the CaOpi1p protein were 
essential for filamentous growth then it might be good drug target as it is not conserved in 
humans. All three of these projects revolve around phospholipid biosynthesis in C. 
albicans and each has revealed interesting and sometime surprising aspects of the biology 
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CLINICAL SIGNIFICANCE OF CANDIDIASIS  
        Candida albicans is a dimorphic yeast that can exist in a human host as either a 
harmless commensal, or as an opportunistic pathogen when the host’s immune system is 
impaired. C. albicans is capable of causing host damage (or disease) leading to oral, 
vaginal, cutaneous, or systemic candidiasis (20). In patients that are neutropenic, Candida 
species are associated with severe and deadly systemic candidiasis with a high mortality 
rate (31.8%)(27, 116). In fact, Candida species are the fourth most common cause of 
catheter-related bloodstream infections in hospitalized patients in the intensive care unit, 
and C. albicans is the most commonly isolated species from these infections, giving rise 
to enormous associated personal and economic costs (19). 
        The rise of immunocompromised individuals in our society has provoked a 
significant emergence in the number of patients affected by Candida species. About one-
third of episodes of candidaemia occur in the intensive care unit (ICU). Although non-
albicans Candida species, such as C. glabrata, C. krusei, and C. parapsilosis are 
observed and some have increased resistance to common antifungals, C. albicans was 
still the predominant species, causing up to two-thirds of all cases of invasive candidiasis 
(166). In invasive candidiasis, a delayed treatment initiation is associated with an 
increased mortality, thus empirical therapy strategies become vitally important.   
        Two decades ago, the therapeutic possibilities for invasive candidiasis were 
limited to amphotericin B and azoles, but with the advent of new antifungal agents, such 
as echinocandins (e.g. caspofungin), other therapeutic options have become available 
(148). Though only a few caspofungin resistant cases have been identified so far, this 
indicates that Candida species could develop more wide-spread resistance to this agent 
over time. This dissertation will discuss a new class of proteins that may serve as a source 
(i.e. phospholipid biosynthesis) for urgently needed new antifungal drug targets in C. 
albicans. 
VIRULENCE FACTORS OF C. ALBICANS 
Morphogenetic conversions 
            C. albicans is a polymorphic organism that is capable of converting between yeast, 
pseudohyphal, and hyphal forms (Fig 1-1, all tables and figures are in the appendix D). 
The conventional view has been that yeast forms are associated with passage through the 
blood stream or commensal carriage, whereas hyphal forms were associated with tissue 




of C. albicans that were locked into the yeast form are avirulent (98). However, this 
concept has been challenged by Braun et al., who found that a TUP1-deficient C. albicans 
strain that is constitutively hyperfilamentous is also avirulent in a murine model of 
systemic candidiasis (15). So far, the precise nature of the association between fungal 
morphogenesis and host invasion is still in debate. However, it is now widely accepted 
that the ability to undergo morphogenetic conversion, rather than the morphological form 
itself, is the primary determinant of pathogenicity (57).  
Adhesion to host cells 
           Adherence of C. albicans to host cells is seen as an essential early step in 
establishing disease. Moreover, C. albicans can also adhere to the surfaces of medical 
devices and form biofilms, which are relatively resistant to many common antifungal 
agents. The ability to form biofilms exhibits a positive association with the degree of 
virulence.  There are several adhesion molecules (adhesins) in C. albicans.  These 
adhesins are part of a structurally related superfamily of fungal adhesins, and in C. 
albicans include Hwp1p, Eap1p and the eight known members of the agglutinin-like 
sequence (ALS) family of adhesins (72, 94, 157). All of these adhesins are 
glycosylphosphatidylinositol (GPI)-anchored proteins that are believed to be cell wall 
proteins (GPI-CWPs). The GPI-CWPs all have N-terminal signal peptides for 
translocation into the ER, and C-terminal signals that mediate GPI membrane anchor 
addition (171). The GPI-anchor is believed to mediate attachment to cell wall glucan 
(164). One protein that is not in the GPI-CWP class that was initially described as an 
adhesin, Int1p (49, 50), is described in this chapter as well.  
            The ALS family of C. albicans includes eight genes (ALS1-ALS7, and ALS9) that 
encode large cell-surface GPI-CWP adhesins that are primarily involved in host-pathogen 
interactions and appear to have differing roles in adhesion and transmigration (72). ALS3 
and ALS8 represent a single locus (186). Several of the ALS genes have been 
characterized and appear to play roles in virulence.  Evidence shows that ALS1-
transformed Saccharomyces cerevisiae exhibits up to 100-fold greater adherence to 
endothelial cells (156). In addition, Als1-deficient C. albicans  hyphae exhibit reduced 
adhesion to endothelial cells (186). Delayed filamentation of the als1∆/als1∆ mutant and 
the flocculation of the strain overexpressing Als1p led to the conclusion that Als1p is 
similar to Flo11p of S. cerevisiae (164). Similarly, S. cerevisiae transformed with ALS3 
shows increased adhesion (156), while Als3-deficient hyphal forms of C. albicans exhibit 




defective adhesion to endothelial cells (186).  ALS3 is also necessary for biofilm 
formation in vitro and it mediates endocytosis by epithelial cells (127, 138). In contrast, 
mutational analysis has shown that deletion of ALS5, ALS6, or ALS7 results in increased 
adhesion of yeast forms of C. albicans to endothelial cells, suggesting an antiadhesive 
role for these proteins (187). 
Hyphae cell wall protein (HWP1) 
 HWP1 encodes a major C. albicans hyphae cell wall protein which is a substrate 
of mammalian transglutaminases and could promote the cross-link of the fungus to 
epithelial cells. Hwp1p is an important developmentally regulated adhesin and found on 
surfaces of germ tubes, but not yeast or pseudohyphal forms of C. albicans. Surface 
localization, expression in host tissues and importance in systemic candidiasis have been 
rigorously demonstrated for Hwp1 (157, 158, 164). C. albicans hwp1Δ/hwp1Δ mutants 
exhibited avirulence whereas HWP1/hwp1Δ  or wild-type exhibietd full virulence (164). 
Hwp1p is also involved in mating and biofilm formation in vitro and in vivo (35, 127). 
 Extracellular hydrolases  
Integrin-like protein (INT1) 
            Int1p is an integrin-like protein not in the GPI-CWP class, but implicated in 
adhesion properties which binds to host extracellular matrix protein. Although Int1p has 
motifs reminiscent of mammalian integrins, it has been shown to be similar to Bud4p of S. 
cerevisiae in primary amino acid sequence, in co-localizing with septins and in 
functioning in bud site selection (49, 50). The int1Δ/int1Δ mutant exhibited reduced 
mortality compared to the wild-type strain, but increased C. albicans persistence in the 
kidney (8). 
            Hydrolase production is known to play a central role in the pathogenicity of 
bacteria, protozoa, and pathogenic fungi (150). The production of hydrolases may play 
more direct role in contributing to host tissue invasion by digesting host cell membranes 
and molecules of the host immune system to enhance invasion and to avoid antimicrobial 
attack, respectively (20). C. albicans secretes three major hydrolytic enzymes:  secreted 
aspartyl proteases (Sap), phospholipases, and lipases. Glucanases and chitinases have 
also been identified, but not linked to virulence (150).  
            The Sap family contains 10 members, SAP1-10, that are all found extracellularly.  
Sap1-8 are secreted into the media, but proteases SAP9 and SAP10 are GPI-anchored and 
associated with the cell periphery. Interestingly, all secreted Candida proteases belong to 




the same class of aspartic proteases. Serine-, metallo-, or cysteine- proteases have not 
been identified in pathogenic Candida (20). Saps have been one of the most 
comprehensively studied virulence factors. Of the SAPs, Sap2, has been the most 
extensively studied.  Sap2p has been crystallized, and it is the most abundant secreted 
protein in vitro when grown in the presence of protein as the sole source of nitrogen (33, 
73). Sap1 to Sap3 are preferentially expressed in acidic pH (also their pH optima for 
proteolytic activity), while Sap4 to Sap6 are preferentially made in neutral environments 
and are believed to be corregulated with filamentous growth.   Sap1 to Sap3p are 
associated with mucosal infection while Sap4 to Sap6 are associated with invasive 
disease, although both of the subgroups also are known to have overlapping functions 
(123).   
         C. albicans isolates from patients with vaginal candidiasis were significantly more 
proteolytic than isolates from asymptomatic vaginal carriers (37). C. albicans isolates 
from HIV-positive women with vaginitis also produced significantly higher levels of 
protease than did C. albicans strains isolated from HIV-positive asymptomatic carriers or 
HIV-negative subjects with candidal vaginitis (39). 
 Phospholipase 
           To date, only two secreted phospholipases have been identified.  These 
phospholipases are both of the B subfamily and are encoded by the genes PLB1 and 
PLB2. In a mouse model of systemic candidiasis, the virulence of C. albicans 
plb1∆/plb1∆ mutant, which had only 1% of the extracellular phospholipase B activity of 
the wild-type strain, was shown to be significantly attenuated (90). Importantly, 
immunogold electron microscopy studies showed that C. albicans secretes 
phospholipases during the infectious process (54). The function of phospholipases during 
C. albicans infections are not precisely known, but they have been implicated in host cell 
penetration and may interact with host signal transduction pathways (150).  
Lipase 
            The first lipase gene LIP1 was cloned in C. albicans in 1997 (47). Nine further 
members of this lipase gene family (LIP2 to LIP10) were subsequently cloned and 
characterized by Hube and his colleagues (75). These secreted lipases may have functions 
other than solely providing nutrients for the cells. However, the roles and functions of 
lipases during C. albicans infections remain to be elucidated (20).  The LIP8 gene has 
been shown to be required for virulence in a mouse model of systemic candidiasis based 




ANTIFUNGALS AGAINST C. ALBICANS AND OTHER HUMAN PATHOGENS 
            There are five major classes of antifungals used against fungal infections (43, 
53) (Fig 1-5). The total number of approved systemic antifungal drugs was only 14 in 
2004 (43). The relatively few classes of antifungal drugs will restrict clinicians’ 
therapeutic choices and these choices are further reduced by the emergence of drug 
resistance (21). The development of new class of drugs will provide combination therapy 
more flexibility and may provide better treatment (78). Therefore, new drug targets are 
urgently needed.  
Polyenes 
            In the 1950s, Amphotericin B (AmB) was released and has been served as the 
standard systemic antifungal therapy (51), but it is often poorly tolerated and associated 
with nephrotoxicity. The function of polyene agents is to directly bind to ergosterol which 
is the fungal equivalent to cholesterol, and is unique in the fungal cell membrane.  
Binding of ergosterol by polyenes alters cell permeability resulting in cell death. The 
lipid derivatives of amphotericin B, particularly liposomal amphotericin B (LAmB) may 
be less nephrotoxic while maintaining a broad antifungal spectrum.  
Flucytosine 
             In the early 1970s, flucytosine (Ancobon) was released by Valeant 
Pharmaceuticals Inc. and became an alternative systemic therapeutic option in addition to 
AmB. Flucytosine is a pyrimidine analog that inhibits both DNA synthesis and protein 
synthesis in the fungal cell (175). However, the toxicity of this agent and the rapid 
development of resistance resulted in limited use for treatment (139). 
Azoles 
            In 1979, the first systemic azole antifungal drug, ketoconazole, was released. 
Azoles exert their antifungal activity by blocking the demethylation of lanosterol, thereby 
inhibiting ergosterol synthesis (60). Ketoconazole was also used for topical agent because 
shampoo and cream formulations of ketoconazole have been available for many years 
(151). Ketoconazole was followed chronologically by fluconazole and itraconazole. Each 
agent offers a specific antifungal spectrum. Although fluconazole’s target Erg11p or 
CYP51 in C. albicans has human homolog huCYP51, the fluconazole was developed as a 
drug (136). However, azoles exhibit fungistatic activity and drug resistance, a growing 
problem among fungal pathogens including C. albicans.  It is particularly problematic in 





            This class includes naftifine and terbinafine, and inhibit ergosterol synthesis at the 
level of squalene epoxidase. They are selective for the fungal enzyme and have a minimal 
effect on mammalian cholesterol synthesis. Naftifine, the original member of the 
allylamine series, possesses only topical activity, whereas the naftifine analog terbinafine 
is active both topically and orally (12). Terbinafine is active against a wide variety of 
dermatophytes, molds, and dimorphic fungi in which it exerts a fungicidal action. 
However, terbinafine exhibits fungistatic activity against C. albicans and drug resistance 
has been observed (113).  
Echinocandins 
           Echinocandins form the newest class of antifungals. Caspofungin (Cancidas) was 
released by Merck Inc. in 2001. Micafungin and anidulafungin were released afterward 
(43). The spectrum of activity is limited to pathogens that rely on these glucan polymers 
and is less than the spectrums of the polyenes or azoles.  Echinocandins are semisynthetic 
lipopeptides, which inhibit synthesis of β-1,3-glucan, an essential and major fungal cell 
wall component (80). Because there is no cell wall in mammalian cells, the 
echinocandins are less toxic than polyenes antifungals.  For example, caspofungin has 
been emerging as first-line therapy for invasive candidiasis due to less toxicity and 
fungicytotic activity (184). Caspofungin can kill most Candida  and Aspergillus species 
(Table 1-1) and only rare resistant strains have been identified. Moreover, Cryptococcus 
neoformans is naturally resistant to caspofungin (105). It is highly possible that 
susceptible fungi will develop resistance over time as this has been observed to a limited 
extent.  
PHOSPHOLIPID BIOSYNTHETIC PATHWAYS MAY SERVE AS A GOOD SOURCE 
FOR NOVEL  ANTIFUNGAL TARGETS IN C. ALBICANS 
Phospholipid biosynthesis in yeast 
            The major phospholipids found in growing cells of S. cerevisiae and C. albicans 
are PC, PE, PI, and PS. Phospholipid composition can vary dramatically when culture 
conditions (i.e. inositol supplementation or starvation) are altered (81). The total lipid 
content of C. albicans was 5% of the dry weight while phospholipids and sterols 
represented 1.1% and 1.2% of the dry weight, respectively (104). In an azole-sensitive C. 





(15.5%) and PI (7.9%) (100). In the plasma membrane of S. cerevisiae, PS (34%) 
constitutes the major phospholipid, then PE (20%), PI (18%), PC(17%) while in the 
mitochondria, PC (51%) is major phospholipid, then PE (25%), PI (13%), and PS (1%) 
(13).   
            The genes involved in C. albicans phospholipid biosynthesis have not been 
studied, however, this fungus has homologs of the genes found to be required for 
phospholipid biosynthesis in S. cerevisiae, therefore S. cerevisiae is used as a model with 
which to explore the process in C. albicans. There are two main pathways for generating 
the aminophospholipids phosphatidylethanolamine (PE), and phosphatidylcholine (PC), 
and one pathway each for generating phosphatidylserine (PS) and phosphatidylinositol 
(PI) (Fig 1-2).  Of all of these enzymes, the PS synthase Cho1p is one of the only ones 
that is not conserved in humans. Cho1p is localized to the endoplasmic reticulum (ER), 
and catalyzes the formation of PS from the precursors serine and cytidine diphosphate-
diacylglycerol (CDP-DAG) along with the release of CMP (Fig 1-3A). PS serves as a 
precursor for the synthesis of PE and ultimately PC by the de novo aminophospholipid 
pathway (Fig 1-2).  First PS is decarboxylated to PE by one of two enzymes, Psd1p and 
Psd2p (Fig 1-3B). Psd1p and Psd2p are mainly localized in the inner mitochondrial 
membrane and Golgi complex membrane, respectively. In the de novo pathway, PE is 
then used as a substrate to form PC by two phospholipid methyltransferases, Cho2p and 
Opi3p. Three methylations of PE are required to form PC, and Cho2p transfers the first 
methyl group to PE to form phosphatidylmonomethylethanolamine (PMME). PMME is 
then converted by Opi3p to phosphatidyldimethylethanolamine (PDME) and then PC via 
the addition of a second and third methyl groups, respectively.  As an alternative 
mechanism for making PE and PC, the cells can rely on the Kennedy pathway so long as 
exogenous choline or ethanolamine are present as substates (Fig 1-2). The Kennedy 
pathway has two branches: CDP-ethanolamine and CDP-choline, which produce PE and 
PC, respectively by utilizing exogenous ethanolamine and choline. In the CDP-
ethanolamine pathway, exogenous ethanolamine is converted to phospho-ethanolamine 
(Etn-P) by ethanolamine kinase (Eki1p).  The Etn-P is converted to CDP-ethanolamine 
by phosphoethanolamine cytidylyltransferase (Ect1p). The CDP-ethanolamine is then 
finally converted to PE by ethanolaminephosphotransferase (Ept1p). In CDP-choline 
pathway, exogenous choline is converted to phospho-ethanolamine (Etn-P) by 
ethanolamine kinase (Eki1p).  The Etn-P is converted to CDP-ethanolamine by 




phosphoethanolamine cytidylyltransferase (Ect1p). The CDP-ethanolamine then is 
converted to PE by ethanolaminephosphotransferase (Ept1p). Though Kennedy pathways 
are not major ways of PE and PC production in yeast, they do play roles for phospholipid 
biosynthesis. 
            The phospholipid PI is formed from the precursors inositol and CDP-DAG by 
phosphatidylinositol synthase (PIS1) (Fig 1-2).  Although there is only one enzyme in 
yeast to generate PI, the inositol precuror may come from one of two sources.  It can 
either be made de novo via a cyclization reaction in which glucose-6-phosphate is 
converted to inositol-3-phosphate by the Ino1p enzyme.  Inositol-3-phosphate is then 
dephosphorylated to inositol by an inositolmonophosphatase encoded by INM1 or INM2.  
Alternatively, inositol may be imported from the extracellular environment via the 
inositol transporters Itr1p or Itr2p.  
            The regulation of the inositol level in the cell is very important, and the rates of 
synthesis of most phospholipid biosynthetic genes are controlled by a set of transcription 
factors that themselves are regulated by inositol levels.  These transcription factors 
regulate de novo inositol biosynthesis by controlling expression of the inositol-3-
phosphate synthase gene, INO1, as well as other genes (24). Ino2p and Ino4p activate the 
expression of the genes encoding for inosiol-3-phosphate synthase (INO1) and other 
phospholipid biosynthesis genes including CHO1, CHO2, and OPI3, while Opi1p 
represses the expression of these genes (Fig 1-2). The Opi1p repressor was named by its 
mutant phenotype of overproduction of inositol (59).  Opi1p is a leucine zipper protein 
with two poly-glutamine rich domains but there is no evidence that this protein binds to 
Regulation of phospholipid biosynthesis in yeast 
            The regulation of phospholipid biosynthetic enzymes by inositol has been 
extensively studies in S. cerevisiae. The factors that regulate phospholipid biosynthesis 
include choline, ethanolamine, and lipids (e.g. phosphatidic acid) (23, 58, 99), but 
inositol has the strongest effect. Inositol is the rate limiting reagent in PI biosynthesis and 
de novo synthesis rates of inositol do not supply as much inositol for PI biosynthesis as 
imported inositol when concentrations are high (i.e 75µM).   Thus, addition of inositol to 
the medium results in an increase in PI biosynthesis and subsequent decreases in levels of 
PC, PE, and PS (23).  This is because both PI and PS are made from a common pool of 
CDP-DAG.  As PI synthesis increases and CDP-DAG is consumed more rapidly for this 
branch of the pathway, PS synthesis is decreased and as a result the downstream 




DNA directly. In the absence of exogenous inositol, Opi1p binds to phosphatidic acid 
(PA) in the endoplasmic reticulum (ER), hence its ability to translocate to the nucleus to 
interact with Ino2p is limited (99). In the presence of inositol, PA levels are decreased 
because PA is a precursor for PI biosynthesis, hence Opi1p is released from the ER and 
rapidly translocates to nucleus where it inhibits transcription of genes such as INO1, 
CHO1, CHO2, and OPI3.  It inhbits transcription by binding to the Ino2p component of 
the Ino2-Ino4p heterodimeric transcriptional activator, which is bound at the upstream 
activating sequence for inositol biosynthesis (UASINO) located on the promoters of the 
above target genes (58). Opi1p has an Ino2p interacting domain, and Ino2p has an Opi1p 
interacting domain, and these have been demonstrated by in vitro co-purification 
experiments (67, 174).  
            Moreover, inositol phosphorylceramide (IPC) synthase which utilizes PI to 
synthesize sphingolipids, is also regulated by inositol. IPC synthase activity is elevated in 
wild-type cells supplemented with inositol (85). 
Acquisition of phospholipid metabolite inositol in C. albicans and other human 
pathogens 
            In order to cause an infection, microbes must be able to live and grow inside the 
host. This necessitates the acquisition of essential nutrients by the pathogen. The 
pathogen must either obtain these nutrients from the host or synthesize the nutrients de 
novo from more basic compounds. The biosynthesis of phospholipids is an area that has 
received considerable attention both in terms of the insight it may give us regarding host 
pathogen interactions as well as the possibility that an understanding of phospholipid 
metabolism may help in the identification of new drug targets (172). Phospholipids are 
complex molecules that are essential for membrane integrity and intracellular signaling. 
The biosynthesis of these compounds requires a complex ordered set of biochemical steps 
involving a number of enzymes (58, 169, 172). An area of particular interest to 
pathogenic microbiologists is understanding how pathogens acquire basic molecules for 
the synthesis of phospholipids (172) such as myo-inositol, serine, choline or 
ethanolamine. In the last several years a number studies have been performed to elucidate 
the roles that proteins involved in myo-inositol acquisition play in controlling virulence 
and/or viability in a several divergent pathogens (25, 108, 109, 118). Several of these 
pathogens’ acquisition systems are summarized in Fig 1-3. 
            Since the roles of virulence of inositol acquisition was described in C. albicans by 




virulence of   Mycobacterium tuberculosis and Trypanosoma brucei. The prokaryotic 
pathogen M. tuberculosis, the causative agent of most cases of tuberculosis, can acquire 
inositol via de novo biosynthesis or import from environment. The Mtino1 mutant 
exhibited inositol auxotrophy, but only high concentration of inositol (77mM) could 
rescue mutant’s growth to wild-type level of growth. In addition, Mtino1 mutant 
exhibited avirulence in SCID mice (118). In the parasite T. brucei, which causes fatal 
sleeping sickness, the TbINO1 gene was shown to be necessary for inositol biosynthesis, 
efficient GPI biosynthesis, and even viability in vitro. The Tbino1 mutants are inviable 
due to insufficient GPI production (108, 109).  
 Since these two very different pathogens both require de novo inositol 
biosynthesis to cause disease or grow, it suggests the possibility that other pathogens will 
have similar requirements.  Thus, in chapter two we will describe a study that explores 
whether the fungal pathogen Candida albicans also requires de novo inositol biosynthesis 
to cause disease.   
Phospholipid biosynthetic enzymes as drug targets in human pathogens 
            Effective drugs to treat various infectious diseases commonly work by targeting a 
pathway or activity that is crucial to the pathogen but not to the host. The target needs to 
be essential for pathogen’s survival, and its inhibition should cause a cytotoxic effect 
rather than a cytostatic effect. Several groups have been identified phospholipid 
biosynthetic pathways as novel drug targets in fungal and parasitic pathogens (102, 182) 
(Table 1-2). Hence, the phospholipid biosynthetic pathway might serve as an Achilles’ 
heel of human pathogens.  
            This part of the introduction will revolve around examples of phospholipid 
biosynthetic enzymes in bacteria, fungi, and parasites that may one day serve as drug 
targets. They include IPC synthase, serine-decarboxylase phosphoethanolamine 
methyltransferase (SDPM), PC synthase, and PS synthase, which are critical for 
pathogens’ growth and have no homologs in human.  
            Sphingolipids play roles as structural components of eukaryotic cellular 
membranes. In yeast, as in mammalian cells, the first and apparently rate-limiting step in 
sphingolipid metabolism involves the condensation of serine and palmitoyl-CoA in the 
endoplasmic reticulum (ER) by serine palmitoyl transferase (SPT) (Fig 1-6). SPT was 
shown to have two homologous subunits LCB1 and LCB2, both of which are required for 
its activity. A third gene required for optimal SPT activity was identified as TSC3. After 




the initial condensation of serine and palmitoyl-CoA into 3-keto dihydrosphingosine, it is 
converted to dihydrosphingosine by the enzyme 3-keto reductase. The reductase was also 
identified as TSC10. The next step in yeast sphingolipid synthesis appears to diverge 
between yeast and mammalian cells. In yeast, dihydrosphingosine (DHS) is hydroxylated 
into phytosphingosine, whereas in mammalian cells, dihydrosphingosine appears to be 
acylated to dihydroceramide before its reduction. The next step in yeast sphingolipid 
synthesis involves the acylation of the long chain base (LCB), phytosphingosine to 
phytoceramide. Ceramides in yeast are next incorporated into complex sphingolipids that 
are different from mammalian sphingolipids in that the head group is comprised of an 
inositol phosphate (IP) instead of a choline phosphate. PI acts as the donor for inositol 
phosphate. The enzyme involved in this step is encoded by Aur1p, an essential protein in 
yeast (122). This enzyme is also a target for another fungal toxin called aureobasidin, and 
because it is not present in mammalian cells, it has emerged as a potentially important 
target for anti-fungal drugs. IPC is further mannosylated in the Golgi to MIPC and MIP2C 
by the enzymes Csg1p, Csg2p, and Ipt1p (41). 
            The fungal inositolphosphotransferase (Ipt1p), which is required for biosynthesis 
of  mannosyl diinositol phosphorylceramide MIP2C, was first characterized in S. 
cerevisiae (42). CaIPT1, a ScIPT1 ortholog encoding the M(IP)2C synthase in C. albicans, 
was characterized, but the mutant’s effect on virulence was not assessed (142). Since 
CaIPT1 has no mammalian ortholog (145), it could be a potential phospholipid drug 
target if CaIPT1 is demonstrated to be required for virulence. 
            The Del Poeta group demonstrated that the Cryptococcus neoformans IPC 
synthase mutant (ipc1∆) exhibited reduced virulence in a rabbit animal model of 
cryptococcal meningitis (102). Meanwhile, Denny et al. isolated a functional ortholog of 
AUR1 in parasite Leishmania major, causative agent of Leishmaniasis. Expression of this 
gene in a mammalian cell line led to the synthesis of an IPC-like species, strongly 
indicating that IPC synthase activity was reconstituted. The identification and 
characterization of this protozoan IPC synthase, an enzyme with no mammalian 
equivalent, will raise the possibility of developing anti-protozoal drugs with minimal 





Serine Decarboxylase Phosphoethanolamine Methyltransferase (SDPM) in parasite 
            Parasitic protozoa are surrounded by membrane structures that have different 
proportions of phospholipids relative to the membranes of the host. It was shown that 
some parasites like Plasmodium falciparum have unique phospholipid metabolic 
pathways (172). PC biosynthesis in P. falciparum is of particular interest since it is the 
most abundant lipid, accounting for half of the total PLs in parasite membranes. PC and 
PE comprise 40-50% and 35-45%, respectively, of the parasite’s total plasma membrane 
phospholipid content (172).  This is quite different from the plasma membrane of red 
blood cells in which it resides, where the concentrations of PC and PE are 30.3% and 
26.9%, respectively (141).  
            Salom-Roig and Vial identified that rationally designed choline analogs can 
inhibit Plasmodium de novo PC biosynthesis, and exhibit antimalarial effect. These 
compounds also interact with malarial pigment, which could enhance the antimalarial 
effect. It is likely that they are dual molecules, exerting their antimalarial activity via two 
simultaneous toxic effects on the intracellular intraerythrocytic parasites (172). However, 
a potential problem with choline analogs might arise because choline is the precursor of 
the neurotransmitter acetylcholine. As an alternative approach, the Mamoum group has 
identified a PC biosynthetic enzyme as a possible anti-malarial drug target: serine 
decarboxylase phosphoethanolamine methyltransferase (SDPM) encoded by PfPMT gene 
(182). 
            PfPMT is required for optimum PC biosynthesis, but performs an enzymatic 
activity that is not conserved in mammals. The synthesis of PC in P. falciparum takes 
place via the Kennedy pathway, but phosphocholine for this pathway is supplied by 
importing it from the host or by making phosphocholine via the serine-decarboxylase 
phosphoethanolamine methyltransferase (SDPM) pathway.  The SDPM pathway depends 
on the PfPMT enzyme which methylates phosphoethanolamine to phosphocholine (Fig 1-
7).  This differs from mammals and yeast where PC is made by the Kennedy pathway 
only from imported choline or by the de novo pathway through methylating PE (Fig 1-2). 
Disruption of PfPMT function results in a complete loss of the SDPM pathway.  This 
drop in phosphocholine compromises PC biosynthesis and results in  defects in parasite 
growth, multiplication, and viability, suggesting this gene plays an important role in the 
pathogenesis of intraerythrocytic Plasmodium parasites (182). PfPMT is a member of 
PEAMT family of phosphoethanolamine methyltransferase and has no mammalian 




they could be potential targets for the development of drugs to treat malaria and other 
parasitic diseases. 
Phosphatidylcholine synthase in bacteria 
            The prokaryotic phospholipid biosynthesis pathway is quite different from 
eukaryotic cells. For example, the eukaryotic PC biosynthesis and salvage pathways were 
missing in most prokaryotic species. In addition, phospholipid biosynthesis in prokaryotic 
cells is divergent among species. For example, there is no salvage pathway for PC 
production in E. coli, but a salvage pathway for PC production does exist in Brucella 
abortus (30)(Fig 1-8).  However, the salvage pathway for PC production between 
mammalian cells and B. abortus cells is dramatically different. The mammalian cells use 
the Kennedy pathway, where choline is converted to CDP-choline and then DAG and 
CDP-choline are used to make PC and CMP.  In B. abortus choline and CDP-DAG are 
used to generate PC and CMP (Fig 1-8) in the choline dependent pathway. The PcsA 
mutant, which lacks this activity, exhibits defective mouse spleen colonization (30). 
Therefore, the PC synthase (PcsA) of the B. abortus choline dependent pathway could be 
a potential drug target. In fact, there is no PcsA homolog in mammalian cells based on 
BLAST searches of the PcsA protein against human proteins. Moreover, phospholipid 
methyltransferase (PmtA) of B. abortus which methylates PE to form PC also has no 
mammalian homolog. The PmtA mutant also exhibits defective mouse spleen 
colonization (30). Conover et al. have demonstrated a similar story in Legionella 
pneumophila, a gram-negative respiratory bacteria causing severe pneumonia. L. 
pneumophila exhibited two pathways to synthesize PC either by phospholipid N-
methyltransferase (PmtA) or phosphatidylcholine synthase (PcsA), but the latter pathway 
was demonstrated predominate. The LpPcsA mutant exhibited defective growth in 
marcrophages (31). 
Phosphatidylserine synthase in fungi and bacteria 
            Our lab has demonstrated that phosphatidylserine synthase (CHO1) in C. albicans 
is essential for virulence and cell wall integrity (Chapter 3). The Cho1p orthologs in other 
organisms were obtained (Table 1-3), but there are no human or mammalian orthologs. 
Therefore, Cho1p could be potential drug target.  
            The biological function of PS has been analyzed in S. cerevisiae. Although PS is a 
quantitatively minor phospholipid in most biological membranes, it is important for 
specific cellular functions in addition to its structural role in membrane. In addition to the 




cofactor is as a specific activator of protein kinase C (PKC). PKC plays crucial roles in 
diverse signal transduction pathways (170). PKC contains a C1 and C2 domain, both are 
required for translocation of kinase from cytoplasm to the inner leaflet of the plasma 
membrane. The C2 domain is responsible for the binding of PKC to PS in a calcium-
dependent manner and the specificity for recognition of PS by the enzyme requires the 
lipid second messenger diacylglycerol. Another protein that requires PS for its function is 
cRaf1 protein kinase. Interaction of Raf-1 with PS promotes the translocation of the 
protein to the plasma membrane as well (121). 
           Politino and Kim demonstrated that PS physically interacted with calcineurin, a 
immunosuppressive reagent. The interactions with PS and calcineurin were enhanced by 
Ca2+ which implicates a regulatory role for the Ca2+-binding subunit in this process.  This 
also suggests that Ca2+- and calmodulin-stimulated interactions of calcineurin with acidic 
phospholipids may play a role in regulating the substrate specificity of this 
multifunctional phosphatase (140). A study also highlighted the importance of lipid 
signaling molecules in the development and pathogenicity of clinically important fungi. 
In Cryptococcus neoformans, sphingolipid-derived diacylglycerol has been shown to 
induce the transcription of the putative virulence factor App1, which inhibits the 
phagocytosis of fungal cells by alveolar macrophages, as well as to activate the protein 
kinase C Pkc1, which promotes cell-wall stability and increased melanin production 
(153).  
            Recently, Bukata et al. demonstrated that phosphatidylserine synthase (PssA) is 
required for optimal virulence in B. abortus. The BaPssA mutant exhibited defective 
mouse spleen colonization (18). There is no BaPssA  ortholog found in mammalian cells. 
Taken together, the results show that phosphatidylserine synthase in fungi, and bacteria 









APPENDIX A: TABLES AND FIGURES 
 
Table 1- 1. Antifungal spectrum of activity against common fungi.  





















C. albicans: Candidiasis, Vaginitis, Oral Thrush 
gene product Mutant virulence Reference 
CHO1 Phosphatidylserine 
synthase 
Avirulence in mouse model of systemic 
infection 
Unpublished 
IPT1 Inositol phosphoryl 
transferase 
N/A (hyphal growth abnormal) (142) 
C. neoformans: Meningitis and Meningo-encephalitis 
IPC1 Inositol phosphoryl 
ceramide synthase 
Reduced virulence in a rabbit animal 
model of cryptococcal meningitis 
(102) 
A. nidulans: Aspergillosis 
BarA acyl-CoA-dependent 
ceramide synthase   
 
N/A (Hyphal growth abnormal) (95) 
LagA Ceramide synthase N/A (Hyphal growth abnormal) (95) 
Parasite 





Plasmodium falciparum: Malaria 
PMT Phosphoethanolamine 
methyltransferase 
Defects of parasite growth, multiplication, 
and viability in erythrocytes 
(182) 
Bacterium 
Brucella abortus: Brucellosis 
PssA Phosphatidylserine 
synthase 
Defective for mouse spleen colonization (17) 
PmtA Phospholipid N-
methyltransferase 
Defective for mouse spleen colonization (30) 
Pcs Phosphatidylcholine 
synthase 















Table 1- 3. Cho1p amino acid identity between C. albicans and other organisms. 
Organism Gene % E value 
Candida albicans SC5314 phosphotidylcholine synthase 100% 1e-157 
Pichia stipitis CBS 6054 phosphotidylcholine synthase 81% 1e-122 
Lodderomyces  




Debaryomyces hansenii DEHA2B15686p 73% 4e-109 
Pichia guilliermondii ATCC 6260 hypothetical protein PGUG_02313 72% 5e-104 
Kluyveromyces lactis hypothetical protein 65% 9e-92 
Ashbya gossypii ATCC 10895 AER357Cp 61% 1e-87 
Vanderwaltozyma polyspora  hypothetical protein Kpol_1035p53 62% 2e-87 
Saccharomyces cerevisiae YJM789 phosphatidylserine synthase 61% 5e-87 
Candida glabrata hypothetical protein 60% 3e-86 
Yarrowia lipolytica YALI0D08514p 58% 4e-75 
Penicillium marneffei ATCC 18224 phosphatidylserine synthase 57% 7e-67 
Schizosaccharomyces pombe CDP-diacylglycerol--serine O-  
  phosphatidyltransferase 
54% 3e-64 
Sclerotinia sclerotiorum 1980 hypothetical protein SS1G_10973 62% 4e-64 
Botryotinia fuckeliana B05.10 hypothetical protein BC1G_11334 61% 3e-63 
Neurospora crassa OR74A hypothetical protein NCU02381 55% 8e-63 
Pyrenophora tritici-repentis Pt-1C-BFP phosphatidylserine synthase 54% 2e-62 
Schizosaccharomyces  
    japonicus yFS275 
CDP-diacylglycerol-serine O-     
    phosphatidyltransferase 
53% 6e-62 
Podospora anserina unnamed protein product 54% 7e-62 
Phaeosphaeria nodorum SN15 hypothetical protein SNOG_12017 51% 2e-61 


































Fig 1- 1. Candida albicans can grow in at least three different morphologies. 





































Fig 1- 2. Phospholipid biosynthetic pathways in S. cerevisiae are used as a model to 
explore phospholipid biosynthesis in C. albicans.  
The CHO1 gene encodes the only phosphatidylserine (PS) synthase in yeast, and it 
forms PS de novo from serine and CDP-diacylglycerol (CDP-DAG).  As the de 
novo pathway continues PS is decarboxylated by the enzymes PSD1 or PSD2 to 
generate phosphatidylethanolamine (PE).  PE is methylated by the enzymes OPI3 
and CHO2 to make phosphatidylcholine (PC).  Phosphatidylinositol (PI) is made in 
a separate de novo pathway by PIS1 from CDP-DAG and inositol. The cell may 
also generate PE and PC from imported exogenous ethanolamine (Etn) or choline 
(Cho) and DAG via the Kennedy Pathway. S. cerevisiae and Candida albicans has 
two equally effective mechanisms for obtaining inositol while in the host. It can 
either generate inositol de novo through INO1, or it can import it from the host 

































Fig 1- 3. Biosynthesis of phospholipids. (A), phosphatidylethanolamine (B), and 
phosphoryl-ethanolamine (C).  










Fig 1- 4. Different pathogens utilize diverse strategies for inositol acquisition.  
All three microbes represented in this figure are able to generate inositol (yellow hexagon) 
de novo by first converting glucose-6-phosphate (green hexagon-P) to inositol-3- 
phosphate (yellow hexagon-P) via the enzyme inositol-3-phosphate synthase (Ino1p). 
Next, an inositol monophosphatase (IMPase) dephosphorylates inositol-3-phosphate to 
make inositol. All three microbes have at least some level of inositol transport activity 
through one or more inositol transporters. Mycobacterium tuberculosis: This prokaryotic 
pathogen is able to both synthesize inositol de novo as well as import inositol from the 
environment. However, transport may not be very efficient (as indicated by the dotted 
arrow passing through the inositol transporter) since the Mtino1 mutant must be grown in 
77mM inositol to allow wild-type levels of growth, and mutants lacking the MtINO1 gene 
are avirulent. Trypanosoma brucei: This eukaryotic parasite is able to import inositol 
from the environment or synthesize it de novo. However, according to the current model, 
inositol imported from the environment is utilized primarily in bulk phosphatidylinositol 
(red and yellow phospholipid) production via a phosphatidylinositol synthase (PIS) 
localized to the Golgi complex. Inositol synthesized de novo is primarily used to generate 
phosphatidylinositol that is used for production of glycosylphosphatidylinositol (GPI). 
The de novo inositol is believed to be utilized mostly for GPI production because the 
IMPase that converts inositol-3-phosphate to inositol is localized to the ER where GPI 
synthesis occurs. Mutants lacking TbINO1 are inviable because of diminished GPI 
production. Candida albicans: This fungal pathogen can acquire inositol by de novo 
synthesis or by importing it, and either mechanism is sufficient to support wild-type 






















Fig 1- 5. Targets of systemic antifungal agents. Refer texts for details. 
























Fig 1- 6. Outline of sphingolipid metabolism in Saccharomyces cerevisiae.  













Fig 1- 7. Pathways for the biosynthesis of phosphatidylcholine in P. falciparum.  
The CDP-choline pathway is shown with gray arrows. The SDPM pathway is depicted 
by dotted arrows. PfAAP, amino acid permease; Cho, choline; CDP, cytidine diphosphate; 
CDP-cho, CDP-choline; CDP-Etn, CDP-ethanolamine; Hb, hemoglobin; PC, 
phosphatidylcholine; PE, phosphatidylethanolamine; PfCCT, P. falciparum CTP 
phosphocholine cytidylyltransferase; PfCEPT, P. falciparum choline/ethanolamine-
phosphate transferase; PfCK, P. falciparum choline kinase; PfCP, P. falciparum choline 
permease; PfECT, P. falciparum CTP phosphoethanolamine cytidylyltransferase; PfEK, P. 
falciparum ethanolamine kinase; PfPMT, P. falciparum phosphoethanolamine 
methyltransferase; PPM, parasite plasmamembrane; PVM, parasitophorous vacuolar 
membrane; RBC, red blood cell; RBCM, red blood cell membrane; PfSD, serine 














Fig 1- 8. Possible phospholipid biosynthetic pathways in prokaryotic Brucella abortus 

















Chapter 2: Candida albicans uses multiple mechanisms to acquire the essential  
metabolite inositol during infection 
 
 
This work is lightly adapted from Publication citation: Infection and Immunity. 2008. 
June p.2793-2801 coined by Ying-Lien Chen, Sarah Kauffman and Todd B. Reynolds 




















            Candida albicans is an important cause of life-threatening systemic bloodstream 
infections in immunocompromised patients. In order to cause infections C. albicans must 
be able to synthesize the essential metabolite inositol or acquire it from the host.  Based 
on its similarity to Saccharomyces cerevisiae it was predicted that C. albicans may 
generate inositol de novo, import it from the environment, or both. The C. albicans 
inositol synthesis gene INO1 and inositol transporter gene ITR1 were each disrupted. The 
ino1∆/ino1∆ mutant was an inositol auxotroph, and the itr1∆/itr1∆ mutant was unable to 
import inositol from the medium. Each of these mutants were fully virulent in a mouse 
model of systemic infection. It was not possible to generate an ino1/ino1∆ itr1∆/itr1∆ 
double mutant suggesting that in the absence of these two genes C. albicans could not 
acquire inositol and was inviable. A conditional double mutant was created by replacing 
the remaining wild-type allele of ITR1 in an ino1∆/ino1∆ itr1∆/ITR1 strain with a 
conditionally expressed allele of ITR1 driven from the repressible MET3 promoter. The 
resulting ino1∆/ino1∆ itr1∆/PMET3::ITR1 strain was found to be inviable in medium 
containing methionine and cysteine (which represses the PMET3 promoter), and it was 
avirulent in the mouse model of systemic candidiasis. These results suggest a model in 
which Candida albicans has two equally effective mechanisms for obtaining inositol 
while in the host. It can either generate inositol de novo through Ino1p, or it can import it 

















            Candida albicans is a dimorphic yeast that can exist in a human host as either a 
harmless commensal, or as an opportunistic pathogen when the host’s immune system is 
impaired (20). In patients that are neutropenic, Candida species are associated with 
severe and deadly systemic bloodstream infections with a high mortality rate (31.8%) 
(116). In fact, Candida species are the fourth most common cause of catheter-related 
blood stream infections in hospitalized patients in the intensive care unit, and C. albicans 
is the most commonly isolated species from these infections (19). 
            The ability of any pathogenic microbe to cause an infection depends on the 
organism’s ability to acquire or generate essential nutrients during residence within the 
host. There are several examples of auxotrophies that compromise virulence in C. 
albicans (82). The most notable example is the defect in uracil biosynthesis caused by a 
mutation in URA3. Homozygous URA3 mutants (ura3∆/ura3∆) block the ability of C. 
albicans to grow without uridine supplementation and lead to avirulence. In fact, the 
level of URA3-encoded orotidine 5'-monophosphate decarboxylase activity can be 
correlated with growth and virulence (88). Homozygous mutations in the ADE2 gene, 
which blocks the ability of C. albicans to grow in minimal medium or serum in the 
absence of exogenous adenine also diminish virulence (45). The homozygous mutations 
in the HEM3 gene leading to heme auxotrophy compromise virulence (82). In addition, 
an induced temperature-sensitive serine auxotroph was significantly less virulent than the 
parent strain (106). 
 In contrast to these results, auxotrophies for a number of amino acids including 
serine, lysine, leucine, histidine, and arginine do not appear to compromise virulence 
(106, 128, 155). For example, Noble and Johnson (128) demonstrated that C. albicans 
his1∆/his1∆, his1∆/his1∆ leu2∆/leu2∆, and his1∆/his1∆ arg4∆/arg4∆ auxotrophic 
mutants exhibited wild-type virulence in a mouse model of systemic candidiasis, whereas 
his1∆/his1∆ leu2∆/leu2∆ arg4∆/arg4∆ triply auxotrophic strains were only mildly 
attenuated in virulence compared to the wild-type. These results suggest that there are 
some metabolites such as amino acids that C. albicans can scavenge from the host during 
an infection, while there are other metabolites that it must make de novo such as uracil, 
adenine, and heme. 
 Myo-inositol (referred to here as inositol) is essential for the growth of all 
eukaryotes, and is needed by some bacteria (63). Inositol is involved in many 




signal transduction, and the formation of glycosylphosphatidylinositol (GPI)-anchored 
proteins, which are themselves essential (11, 24, 133, 161). Inositol has been implicated 
in the pathogenicity of C. albicans because it is an essential precursor for 
phospholipomannan, a GPI-anchored glycolipid on the cell surface of Candida which is 
involved in pathogenicity (115).  
 There are three potential sources of inositol available to C. albicans based on 
work that has been done in the related yeast S. cerevisiae: 1) de novo biosynthesis, where 
glucose 6-phosphate is converted to inositol 1-phosphate by the inositol-1-phosphate 
synthase enzyme; 2) inositol import from the extracellular environment by an inositol 
transporter; and 3) recycling of inositol from the dephosphorylation of inositol 
polyphosphate products (24, 125, 161). 
 In S. cerevisiae, de novo inositol biosynthesis and import have both been well 
studied.  The S. cerevisiae inositol 1-phosphate synthase is encoded by the INO1 gene 
(44). The Ino1p enzyme converts glucose-6-phosphate to inositol-1-phosphate, and then a 
second enzyme, inositol monophosphatase, encoded by the INM1 gene, dephosphorylates 
inositol-1-phosphate to create inositol (101). S. cerevisiae carries two distinct inositol 
transporter genes, ScITR1 and ScITR2, which are both capable of importing inositol, but 
at different efficiencies (126).  
 C. albicans carries a putative homolog of INO1 based on sequence similarity 
which was identified and sequenced by Klig et al (Genbank accession #L22737) (83, 84). 
C. albicans INO1  shows 64% identity to S. cerevisiae INO1 at the amino acid level (84). 
In addition, it has been shown that C. albicans has a potent inositol transporter activity 
(77). It was demonstrated that the inositol transporter in C. albicans has an apparent Km 
value of 240±15 µM, which appears to be active and energy-dependent (77). C. albicans 
inositol transport activity differs in substrate and cotransporter specificity from the human 
inositol-Na+ transporter. However, the inositol transporter gene in C. albicans was not 
identified in this previous study. 
 Recently, the importance of inositol biosynthesis in some human infectious agents 
was demonstrated by reports in two unrelated pathogens, Mycobacterium tuberculosis 
and Trypanosoma brucei.  In T. brucei its INO1 homolog was shown to be necessary for 
inositol biosynthesis, efficient GPI synthesis, and growth in vitro (108, 109). In M. 
tuberculosis, it was found that its INO1 homolog was required for de novo inositol 
biosynthesis and full virulence in a mouse model of infection (118).  




albicans. This fungus may be able to both synthesize and import inositol. It became of 
interest to determine if C. albicans would behave like M. tuberculosis and T. brucei and 
require INO1 function for virulence/viability, or if in contrast to these pathogens, C. 
albicans would be able to utilize either de novo synthesis or inositol import to support 
virulence. 
MATERIALS AND METHODS 
Strains and growth media 
        C. albicans strains and plasmids used in this study are shown in Table 2-1 and 
Table 2-2 (see all tables and figures in the appendix A). Media used in this study include 
YPD (yeast extract-peptone-dextrose, 1% yeast extract, 2% peptone, 2% glucose) (163), 
defined medium 199 (M199, Invitrogen), yeast carbon base-bovine serum albumin 
(YCB-BSA) (154), and minimal medium (MM, 0.67% Difco yeast nitrogen base without 
amino acids, 2% glucose) (163). MM medium was supplemented with 75 µM inositol for 
supporting the growth of the C. albicans ino1∆/ino1∆ mutant and 2.5mM methionine and 
cysteine for MET3 promoter shutoff assays (22). Inositol-free media (163) was made for 
testing the phenotype of the ino1∆/ino1∆ mutant. Agar plates were solidified with 2% 
agar (granulated, Fisher) for YPD and with 2% BactoAgar (contains no residual inositol) 
for MM and inositol-free media. 
Strain construction 
    The C. albicans INO1 gene (INO1) was disrupted by using the CaNAT1-FLP 
cassette (154), whereas, the C. albicans ITR1 gene (ITR1) was disrupted by using the 
SAT1 flipper (143).  
    For the INO1 disruption construct, the 564 basepair (bp) 5’ non-coding region 
(NCR) of INO1 was amplified with primers JCO39 and JCO40 (Table 2-3), which 
introduced KpnI and ApaI restriction sites, and was cloned into pJK863 5’ of the 
CaNAT1-FLP cassette (Fig 2-1A). The 583bp 3’ NCR of INO1 was amplified with 
primers JCO41 and JCO42 which introduced SacII and SacI sites, and was cloned into 
pJK863 3’ of the CaNAT1-FLP cassette (Fig 2-1A). This created the INO1 knock out 
construct plasmid pYLC94 (Table 2-2, Fig 2-1A), which was cut with KpnI and SacI to 
release the disruption construct which was transformed into the wild type SC5314 strain 
by electroporation as described previously (36, 143). The disruption construct was used 
to sequentially disrupt both alleles of INO1 as previously described (154).  The INO1 




ORF and 5’ NCR from SC5314 genomic DNA using primers (JCO39 and JCO47) that 
introduced KpnI and SalI sites. This fragment was ligated into the pRS316 vector along 
with a 1.7 Kb fragment containing the NAT1-3’INO1NCR amplified from plasmid pYLC94 
using primers JCO50 and JCO42 which introduced SalI and SacI sites. This resulted in 
the INO1 reconstitution plasmid pYLC119 (Table 2-2, Fig 2-1B). The 3.8Kb KpnI-SacI 
fragment from pYLC119 was transformed into the ino1∆/ino1∆ mutant (YLC113) in 
order to create the reconstituted ino1∆/ino1∆::INO1 strain (YLC120). 
     A similar approach was used to knock out ITR1 with the SAT1 flipper plasmid 
pSFS2A (143). Approximately 500 bp 5’ and 3’ NCRs from ITR1 were amplified using 
the primer pairs JCO89-JCO90 and JCO93-JCO94, respectively, each of which 
introduced restriction sites into the corresponding fragments. The ApaI-XhoI 5’ITR1NCR 
and NotI 3’ITR1NCR fragments were ligated into pSFS2A resulting in the ITR1 knock out 
construct plasmid pYLC164 (Table 2-2, Fig 2-2A). The 5Kb ApaI-SacII fragment from 
pYLC164 was electroporated into SC5314 and used to disrupt both copies of ITR1 by 
sequential disruptions (117, 143). For the reconstituted construct, JCO89 and JCO111 
primers, which added ApaI and EcoRI sites, were used to amplify a 2Kb fragment 
containing the 5’ITR1NCR and ITR1 ORF region, which was used to replace the ApaI-
EcoRI fragment (containing 5’ ITR1NCR-PMAL2-FLP) in the pYLC164 vector resulting in 
pYLC208 (Table 2-2, Fig 2-2B). The 5Kb ApaI-SacII fragment from pYLC208 was used 
to reconstitute ITR1 in the itr1∆/∆ mutant (YLC196) strain creating the itr1∆/∆::ITR1 
strain (YLC211).  
    The ITR1 conditional mutant was made as follows. Using SC5314 genomic DNA 
as template, primers JCO118 and JCO119 (introduced PstI and NotI sites) were used to 
amplify a 1362bp fragment containing the CaMET3 promoter (22), and primers JCO120 
and JCO121 (introduced NotI and SacII sites) were used to amplify the ITR1 ORF. These 
fragments were used to replace the PstI-SacII fragment in pYLC164, which deleted the 3’ 
flanking FRT site, resulting in the conditional ITR1 expression construct plasmid 
pYLC229 (Table 2-2, Fig 2-2C). The 7.6 Kb ApaI-SacII fragment from pYLC229 was 
transformed into the ino1∆/ino1∆ itr1∆/ITR1 strain (YLC184) to create the ino1∆/ino1∆ 
itr1∆/PMET3::ITR1 conditional strains (YLC261 and YLC266). 
Northern blot analysis 
    Northern blotting for ITR1 expression was performed as described (144) with the 
following exceptions. Strains grown in liquid medium 199 at 37°C for 2 hrs were 




containing bps 24-750 of the ITR1 ORF (primers JCO102 and JCO103) was used as a 
probe. Expression was normalized against C. albicans ACT1 gene expression probed on 
the same membrane. The ACT1 probe was generated with the primers JCO48 and JCO49. 
Southern blot analysis 
    Hybridization conditions for the Southern blot analysis were similar to those for 
Northern blot analysis, except that the Techne Hybrigene oven was set to 60°C for the 
incubation step, and 42°C and 60°C for washing steps. The cells were grown in liquid 
YPD at 30°C overnight. The genomic DNA was extracted using the Winston-Hoffman 
method (70) and 20µg of genomic DNA were subjected to Southern blotting. The 
genomic DNA of ino1 mutants was cut by AflII and SphI restriction enzymes while the 
genomic DNA of itr1 mutants was cut by PstI. PCR products containing the ~500bp 3’ 
NCR of INO1 (primers JCO41 and JCO42) and 3’NCR of ITR1 (primers JCO93 and 
JCO94) were used as probes. 
Inositol uptake assays 
        The inositol uptake assay protocol was adapted in part from a protocol of Jin and 
Seyfang (77). The wild type, itr1∆/ITR1, itr1∆/itr1∆, and itr1∆/itr1∆::ITR1 strains were 
grown in YPD liquid cultures overnight at 30°C. Cells were diluted to 1 OD600 in YPD, 
grown at 30°C, and collected at 5 OD600 by centrifugation at 2,600g for 5 min. Cells were 
then washed twice with water at 4°C and resuspended in 2% glucose to a final 
concentration of 2x108 cells/ml as determined by a hemacytometer. From this time point 
on, cells were kept on ice until used for the actual assay. For the uptake assay, the 
reaction mixture (250µl) contained 2% glucose, 40mM citric acid/KH2PO4 (pH5.5), 
0.15µM [2-3H] inositol (1 µCi/µl, MP Biomedicals), and 200µM unlabeled inositol 
(Alexis Biomedicals). Equal volumes of the reaction and cell mixtures (60µl each) were 
warmed to 30°C and mixed for the uptake assay which was performed for 10 minutes at 
30°C. As negative controls, mixtures were kept at 0°C (ice) during the 10 minute 
incubation. One hundred µl aliquots were removed and transferred to pre-wetted metricel 
filters on a vacuum manifold. The filters were washed 4 times each with 1ml ice cold 
water. The washed filters were removed and added to liquid scintillation vials for 
measurements on a Perkin Elmer TRI-CARB 2900TR scintillation counter. The uptake of 






Mouse infection studies 
    Five- to six-week-old male CD1 mice (18 to 20g) from Charles River 
Laboratories were used in this study. Mice were housed at five per cage. For infection, 
colonies from each C. albicans strain were inoculated into 20ml of YPD or MM media. 
Cultures were grown overnight, washed twice with 25ml of sterile water, counted by 
hemacytometer, and resuspended at 107 cells per ml in sterile water. The cells were then 
plated on YPD to determine the viability. Mice were injected via the tail vein with 0.1ml 
of the cell suspension (106 cells) (176), and the course of infection was monitored for up 
to 30 days. At least two independent infections were performed for each strain. Survival 
was monitored twice daily, and moribund mice were euthanized. All experimental 
procedures were carried out according to the NIH guidelines for the ethical treatment of 
animals. 
Statistics 
            The statistical analysis was done using Prism 4.0 software (GraphPad Software). 
For the mouse model of systemic infection, Kaplan-Meier survival curves were compared 
for significance using the Mantel-Haenszel log rank test. Tests for significance of 
differences between inositol uptake strains were determined using the two-tailed unpaired 
t test. Statistical significance was set at P < 0.05. 
RESULTS 
The INO1 gene in C. albicans is required for growth in the absence of exogenous 
inositol  
    The C. albicans homolog of the S. cerevisiae INO1 gene (ScINO1) identified by 
Klig et al (84) was disrupted in order to determine if it was required for inositol 
biosynthesis in C. albicans. The C. albicans INO1 homolog (orf19.7585, which we refer 
to as INO1 in this communication) was disrupted by sequentially replacing both alleles of 
the gene with the NAT1-FLP cassette which contains the nourseothricin resistance gene 
(154). The INO1 disruption construct is diagrammed in Fig 2-1A. The INO1 gene was 
reintegrated into the INO1 locus of the homozygous mutant (ino1∆/ino1∆) using the 
construct shown in Fig 2-1B to verify linkage of any resulting phenotypes with the 
genotype. Wild-type (INO1/INO1), heterozygous (ino1∆/INO1), homozygous 
(ino1∆/ino1∆), and reconstituted (ino1∆/ino1∆::INO1) strains were analyzed by PCR 
(data not shown) and Southern blotting (Fig 2-1C) to confirm the deletion and 




ino1∆/ino1∆::INO1 strains were then compared for growth on medium lacking inositol 
(163) to determine if an ino1∆/ino1∆ mutation would compromise the ability of the strain 
to grow in the absence of inositol. The ino1∆/ino1∆ strain was unable to grow on inositol 
free medium, while the wild-type, heterozygous, and reconstituted strains grew equally 
well. As expected, the ino1∆/ino1∆ strain was able to grow as well as the wild-type on 
identical solid or liquid media with inositol added (Fig 2-1D and data not shown, 
respectively).  
The INO1 gene is not required for virulence in C. albicans 
    The INO1 gene does not appear to be required for virulence in a mouse model of 
disseminated candidiasis. The wild-type, ino1∆/INO1, ino1∆/ino1∆::INO1, and two 
separately derived ino1∆/ino1∆ strains were tested for virulence in the mouse 
disseminated infection model (176). These tests revealed no difference in virulence 
between the wild type and ino1 mutant strains (Fig 2-5A).  
The ITR1 gene is required for inositol transport in C. albicans 
    The fact that the ino1∆/∆ mutant can grow on medium containing inositol 
supports previous studies that have shown that C. albicans harbors an inositol transporter 
(77). A C. albicans homolog of the S. cerevisiae ITR1 and ITR2 transporters was 
identified by BLASTing the ScItr1p and ScItr2p protein sequences against the Candida 
Genome Database (CGD, http://www.candidagenome.org).  This homolog was 
orf19.3526 and is referred to as HGT15  in the CGD, but its alias in CGD is ITR2 . This 
gene has never been characterized functionally.  Based on our BLAST search using CGD, 
C. albicans orf19.3526 is the closest homolog to ScITR1 and ScITR2 and is 51% identical 
to both S. cerevisiae transporter genes over its full length (data not shown). C. albicans 
orf19.3526 also contained the critical inositol transporter motif (D/E)(R/K)φGR(R/K) 
(152). Based on the results described below we will refer to orf19.3526 as ITR1 for the 
rest of this paper. 
    Both alleles of the ITR1 gene were sequentially disrupted by replacing each ORF 
with the nourseothricin resistance cassette from the SAT1 flipper (143). The itr1∆ 
disruption construct is diagrammed in Fig 2-2A. The ITR1 gene was reconstituted in the 
itr1∆/itr1∆ strain using the reconstitution construct shown in Fig 2-2B. Gene deletions 
and replacements were checked for accuracy using PCR (data not shown) and Southern 
blotting (Fig 2-2D). As a further test, Northern blotting revealed that the ITR1 transcript 
could only be detected in wild-type (ITR1/ITR1), heterozygous itr1∆/ITR1, and 




Expression was lower in the itr1∆/ITR1 and itr1∆/itr1∆::ITR1 strains presumably because 
they contain only one allele of the gene. 
 Analysis of inositol uptake in the wild-type, itr1∆/ITR1, itr1∆/itr1∆ and 
itr1∆/itr1∆::ITR1 strains revealed that ITR1 is required for inositol uptake (Fig 2-3). 
Inositol uptake was not detectable at 0˚C [(77) and Fig 2-3], hence this was used as a 
control. Inositol uptake was 58-fold higher at 30˚C than at 0˚C in the wild type. In 
contrast, inositol uptake in the itr1∆/itr1∆ mutant was only 4-fold higher at 30˚C than at 
0˚C, but a two-tailed paired t test analysis revealed that there was no significant 
difference in uptake between these two temperatures (P=0.34). The itr1∆/ITR1 mutant 
showed decreased inositol import compared to the wild type, and the ITR1 reconstituted 
strain restored inositol import to a level similar to that seen in the wild-type.  
        Inositol uptake in the wild type strain in 200µM inositol was found to be 288 
pmol per 5x107 cells during a 10 minute uptake period. Jin and Seyfang showed 
approximately 60 pmol per 5 x 107 cells during a single minute uptake (77). The 
difference between their data and ours is probably due to saturation of uptake over a 10 
minute time course (77). 
The ITR1 gene is not required for virulence in C. albicans 
    The itr1∆/itr1∆ strain does not appear to be any less virulent than the wild type in 
a mouse model of systemic candidiasis. The wild-type, itr1∆/ITR1, itr1∆/itr1∆, and 
itr1∆/itr1∆::ITR1 strains were compared in the mouse model for disseminated infection. 
There was not a significant difference between the virulence of the wild-type and the 
itr1∆/itr1∆ strains (Fig 2-5B, P=0.95).  The itr1∆/ITR1 mutant behaved like the wild-type 
(Fig 2-5B) as well. In the reintegrant strain (itr1∆/itr1∆::ITR1) only half of the mice 
succumbed to the infection.  This may be due to technical error during the injection or an 
uncharacterized mutation within the strain.  The fact that the wild-type, itr1∆/ITR1, and 
itr1∆/itr1∆ strains were all similarly virulent strongly indicates that a lack of ITR1 does 
not impair virulence.    
The INO1 and ITR1 genes show synthetic defects in growth and virulence 
 Although neither ITR1 nor INO1 were required for virulence in a mouse model of 
systemic candidiasis, it was possible that each could compensate for loss of the other 
during infection since it has been shown that rat serum contains 20-100µM inositol (76, 
134) and mouse liver contains approximately 100µM inositol (10). In order to test this 
hypothesis an attempt was made to disrupt both genes simultaneously. One allele of ITR1 




allele of ITR1 suggesting that a double mutant consisting of ino1∆/ino1∆ and itr1∆/itr1∆ 
was synthetically lethal. Therefore, in the ino1∆/ino1∆ itr1∆/ITR1 strain the promoter of 
the remaining wild-type ITR1 allele was replaced with the CaMET3 conditional promoter 
(22) using the construct described in Fig 2-2C. When the CaMET3 promoter (PMET3) is 
used to replace the promoter of a target gene, it represses transcription of that gene in the 
presence of methionine and cysteine in the medium. The correct insertion of the 
PMET3::ITR1 allele into the chromosome was confirmed by PCR analysis (data not shown) 
and Southern blotting (lane 7, Fig 2-2D). The resulting ino1∆/ino1∆ itr1∆/PMET3::ITR1 
strain was tested for growth in minimal medium containing 75µM inositol and either 0 or 
2.5mM methionine and cysteine. It was found that unlike the wild-type or the ino1∆/∆ 
itr1∆/ITR1 strains, two separately derived ino1∆/∆ itr1∆/ PMET3::ITR1 strains failed to 
grow in the presence of 2.5 mM methionine and cysteine (Fig 2-4).  
 The ino1∆/ino1∆ itr1∆/PMET3::ITR1 strain was tested to determine whether its 
virulence was affected in a mouse model of systemic candidiasis. Previous work had 
indicated that the presence of the PMET3 promoter on the essential gene CaFBA1 could 
compromise virulence (147). The methionine in the mouse bloodstream is presumably 
able to prevent expression of the CaFBA1 gene sufficiently to compromise growth and 
virulence in the mouse. The wild-type, ino1∆/ino1∆ itr1∆/ITR1 and two ino1∆/ino1∆ 
itr1∆/PMET3::ITR1 strains were compared in the mouse model of systemic candidiasis. 
This experiment revealed that the ino1∆/∆ itr1∆/ITR1 strain was attenuated for virulence, 
and the ino1∆/ino1∆ itr1∆/PMET3::ITR1 strains were avirulent (Fig 2-5C).  
DISCUSSION 
    The mechanism by which C. albicans acquires the essential metabolite inositol during 
an infection has not been explored previously. We have found that C. albicans is able to 
generate inositol de novo via the INO1 gene product or import inositol from the 
environment via the ITR1 gene product with efficiencies that allow it to establish an 
infection regardless of which mechanism is employed. This conclusion only applies to 
bloodstream infections as this was the only model tested. This result implies that the 
bloodstream content of inositol in mice is sufficient to support an infection even if C. 
albicans must acquire inositol solely by importing it. Although our search of the literature 
did not reveal the estimated inositol content of mouse serum, the inositol levels found in 
rats is 20-100µM (76, 134) and may be comparable to mice and is similar to that found in 




 The results found with C. albicans are in contrast to what has been observed in 
two important human pathogens, M. tuberculosis and T. brucei, which require de novo 
inositol biosynthesis via INO1 homologs in order to be fully virulent (Mt) in mouse 
models or viable (Tb) (109, 118). Both of these pathogenic microbes are capable of 
importing inositol, but in neither case is import sufficient to allow viability in T. brucei or 
virulence in M. tuberculosis. In the case of T. brucei, de novo synthesized inositol is used 
to make GPI-anchored proteins, while imported inositol is used very inefficiently for this 
purpose (108). GPI-anchored proteins are required for viability in T. brucei (97), so 
disruption of INO1 compromises viability. In the case of M. tuberculosis the inositol 
transporter is too inefficient to import inositol from the host in order to support infection 
(118).  
 Unlike either of these pathogens Candida albicans possesses an inositol 
transporter, encoded by ITR1, that is capable of transporting inositol efficiently enough to 
allow full virulence in a mouse model of systemic candidiasis even in the absence of de 
novo inositol biosynthesis. In the case of both M. tuberculosis and T. brucei it has been 
suggested that the development of selective inhibitors of Ino1p homologs might be an 
effective way to generate antimicrobials (108, 118). The data reported in this 
communication indicates that this would not be effective in C. albicans as it is fully 
virulent even in the absence of its Ino1 enzyme. As an alternative approach, it has been 
suggested that toxic inositol analogs that are selectively taken up by the C. albicans 
inositol transporter but not by the human inositol-Na+ transporter, could be effective 
drugs (77). This may be a possibility, although it needs to be determined which of these 
two mechanisms, de novo biosynthesis or import, is used by wild-type C. albicans during 
an infection. If import is used extensively, then this approach might work, however since 
C. albicans is fully virulent in the absence of ITR1, the development of resistant mutants 
lacking Itr1p transporter function could be a problem.  Nonetheless, a toxic analog might 
be useful in combination with drugs affecting other targets such as an azole or polyene 
(2). 
 Based on our results it appears that Itr1p is the primary and perhaps sole inositol 
importer in C. albicans both in vitro and during infection. Disruption of ITR1 greatly 
inhibits inositol uptake in vitro (Fig 2-3), and in the absence of INO1 a strain carrying 
only the PMET3::ITR1 allele of ITR1 cannot grow in medium containing cysteine and 
methionine, even in the presence of 75 µM extracellular inositol (Fig 2-4). The amount of 




from the MET3 promoter as well, which is consistent with results using a MET3 driven 
form of the C. albicans FBA1 gene (147). Our conclusion that ITR1 is the primary or sole 
inositol transporter is consistent with a previous study of C. albicans inositol transport 
which concluded that there was one inositol transporter in C. albicans that was 
responsible for all, or at least the vast majority of, inositol transport activity (77).  
 The situation in C. albicans contrasts with S. cerevisiae, which has two inositol 
transporters that are expressed at widely different levels (126). In S. cerevisiae, the 
ScItr1p transporter is the most highly expressed of the two transporters and accounts for 
most of the transport activity. The residual transport activity in S. cerevisiae is carried out 
by ScItr2p, which is expressed at much lower levels. Based on BLAST searches of the 
Candida Genome Database using ScITR1 or ScITR2 as queries, the C. albicans ITR1 
gene was the closest homolog to the S. cerevisiae inositol transporters showing 51% 
identity over the whole sequence to either ScITR1 or ScITR2. C. albicans carries at least 
one other homolog of the S. cerevisiae inositol transporters that is predicted to have 12 
transmembrane domains and the (D/E)(R/K)øGR(R/K) motif typical of inositol 
transporters. The predicted protein sequence of this gene (orf19.5447, HGT19) bears 26% 
and 27% identity to ScItr1p and ScItr2p, respectively. It is possible that orf19.5447 
encodes an inositol transporter, but our results suggest that if so, this other transporter is 
expressed at too low of a level to transport inositol efficiently or it is expressed in 
different conditions than those tested in our experiments. Alternatively, it is a very low 
affinity transporter like that seen in M. tuberculosis (118) or it transports molecule other 
than inositol. 
 Taken together our results indicate that either Ino1p or Itr1p can supply the 
inositol requirement during an infection, but a number of questions remain to be 
answered. For wild-type C. albicans it is not known whether de novo inositol 
biosynthesis or import is utilized during an infection or a combination of both are in 
operation. It may be variable depending on the distribution of C. albicans cells within the 
host. In addition, it is not known whether de novo synthesis or import is favored during 
growth in other host niches such as the gut, the oral mucosa, and the vaginal tract. This 
again may be variable depending on the nutrient conditions of the particular host niche 
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APPENDIX B: TABLES AND FIGURES 
 
Table 2- 1. C. albicans strains 
Strain Parent Genotype Source of reference 
SC5314 
(wild-type) Clinical isolate Prototrophic wild type (55) 
YLC100 SC5314 ino1Δ::NAT1-FLP/INO1 This study 
YLC105 YLC100 ino1Δ/INO1 This study 
YLC111 YLC105 ino1Δ/ino1Δ::NAT1-FLP This study 
YLC113 YLC111 ino1Δ/ino1Δ This study 
YLC120 YLC113 ino1Δ/ino1Δ::INO1 This study 
YLC101 SC5314 ino1Δ::NAT1-FLP/INO1 This study 
YLC108 YLC101 ino1Δ/INO1 This study 
YLC126a YLC108 ino1Δ/ino1Δ::NAT1-FLP This study 
YLC176 SC5314 itr1Δ::SAT1-FLP/ITR1 This study 
YLC185 YLC176 itr1Δ/ITR1 This study 
YLC192 YLC185 itr1Δ/itr1Δ::SAT1-FLP This study 
YLC196 YLC192 itr1Δ/itr1Δ This study 
YLC211 YLC196 itr1Δ/itr1Δ::ITR1 This study 
YLC180 YLC113 ino1Δ/ino1Δ itr1Δ::SAT1-FLP/ITR1 This study 
YLC184 YLC180 ino1Δ/ino1Δ itr1Δ/ITR1 This study 
YLC261 YLC184 ino1Δ/ino1Δ itr1Δ/SAT1-PMET3-ITR1 This study 
YLC181 YLC113 ino1Δ/ino1Δ itr1Δ::SAT1-FLP/ITR1 This study 
YLC187 YLC181 ino1Δ/ino1Δ itr1Δ/ITR1 This study 
YLC266b YLC187 ino1Δ/ino1Δ itr1Δ/SAT1-PMET3-ITR1 This study 
a another separately derived ino1Δ/ino1Δ homozygous mutant. 








Table 2- 2. Plasmids 
Plasmids Characteristics Source of reference 
pJK863 CaNAT1-FLP cassette carrying nourseothricin resistance gene (154) 
pSFS2A SAT1 flipper carrying nourseothricin resistance gene (143) 
pYLC94 pJK863 flanked 5’ and 3’ INO1NCR for INO1 gene knock out This study 
pYLC119 INO1 reconstitution construct This study 
pYLC164 pSFS2A flanked 5’ and 3’ ITR1NCR for ITR1 gene knock out This study 
pYLC208 ITR1 reconstitution construct This study 







Table 2- 3. PCR primers 
Primer Use Sequence (5’  3’) 
JCO39 Disrupt INO1 AAAAAAGGTACCGGGATCAAACAATCTAGACTCAC 
JCO40 Disrupt INO1 AAAAAAGGGCCCAGTTATTTGTTTGTGAAGGAGAT 
JCO41 Disrupt INO1 AAAAAACCGCGGTGTTGCTTTATAGTAATATCGCT 
JCO42 Disrupt INO1 AAAAAAGAGCTCCGACAGCCCATATATTTTAATCG 
JCO47 Restore INO1 AAAAGTCGACTGATTATTTGAGAATTCTTTC 
JCO50 Restore INO1 AAACGTCGACACTGGATGG 
TRO369 Confirm ino1Δ GCACGTCAAGACTGTCAAGG 
JCO105 Confirm ino1Δ TTATCTATTGTCAATTTCGCC 
JCO106 Confirm ino1Δ TGGGAGTTTAGTGTTTGAGC 
JCO89 Disrupt ITR1 AAAAAAGGGCCCCTCAACAAATTGTCGATTAT 
JCO90 Disrupt ITR1 AAAAAACTCGAGTTCCCTCAAATCAATACACT 
JCO93 Disrupt ITR1 AAAAAAGCGGCCGCCTCAGTCTAGTATACTAAAT 
JCO94 Disrupt ITR1 AAAAAAGCGGCCGCTGAAATACTTGAACTGTGTGA 
JCO95 Confirm itr1Δ GATTATTAGTTAAACCACTGC 
JCO96 Confirm itr1Δ TGAAGGGGGAGATTTTCACT 
JCO100 Confirm itr1Δ AAACCCCCACTTGAGTCTAA 
JCO101 Confirm itr1Δ TTGATCATTTGACCTCGGCA 
JCO111 Restore ITR1 AAAAAAGAATTCGAGCTATACGGTTGGTTTCGA 
JCO118 ITR1 conditional construct AAAAAACTGCAGAAAACTACGAACAATTGTC 
JCO119 ITR1 conditional construct AAAAAAGCGGCCGCGTTTTCTGGGGAGGGTATTT 
JCO120 ITR1 conditional construct AAAAAAGCGGCCGCATGGGAAGTTCAACCAATAA 
JCO121 ITR1 conditional construct AAAAAACCGCGGCTATACGGTTGGTTTCGATT 
JCO102 ITR1 Northern blot probe ACAATCAAAAGCTACCCCCA 
JCO103 ITR1 Northern blot probe TGGTGTATCTGGTAAAAACCA 
TRO562 INO1 Northern blot probe GAAAACTCTGTTGTTGAAAAAGATG 
TRO563 INO1 Northern blot probe TTGTTGGCACGTTCACTTTG 
JCO48 CaACT1 Northern blot probe CCAGCTTTCTACGTTTCC 











Fig 2- 1. The INO1 gene was disrupted in C. albicans.  
(A) Structure of the INO1 disruption construct. Approximately 500 base pairs of non-
coding DNA flanking the 5’ and 3’ ends of the INO1 gene (5’-and 3’-INO1NCR, 
respectively) were cloned onto either flank of the CaNAT1-FLP construct (154).  The 
thick dark arrows represent the FRT target sights of the FLP recombinase.  The ball and 
stick represents the ACT1 terminator (ACT1t) and the thinner arrow on a raised line 
represents the SAP2 promoter (PSAP2). (B) The INO1-NAT1 construct used to reintegrate 
INO1 ORF into the ino1∆/∆ mutant. (C) Southern blotting was used to confirm the INO1 
disruptions. Lane 1 (wild-type); lane 2 (ino1Δ::NAT1-FLP/INO1), lane 3 (ino1Δ/INO1); 
lane 4 (ino1Δ/Δ:: NAT1-FLP); lane 5 (ino1Δ/Δ); lane 6 (ino1Δ/Δ::INO1). (D) The INO1 
gene is required for growth in the absence of exogenous inositol. The cells were streaked 







Fig 2- 2. The ITR1 gene was disrupted in C. albicans.  
(A) Structure of the ITR1 disruption construct. Approximately 500 base pairs of non-
coding DNA flanking the 5’ and 3’ ends of the ITR1 gene (5’-and 3’-ITR1NCR, 
respectively) were cloned into the pSFS2A plasmid such that they flanked the SAT1 
flipper cassette. The thick dark arrows represent the FRT target sights of the FLP 
recombinase.  The ball and stick represents the ACT1 terminator (ACT1t) and the thinner 
arrow on a raised line represents the MAL2 promoter (PMAL2). (B) The ITR1-SAT1 
construct used to reintegrate ITR1 ORF into the itr1∆/∆ mutant. (C) The PMET3::ITR1 
construct used to replace the ITR1 allele in the ino1∆/∆ itr1∆/ITR1 strain to generate the 
ITR1 conditional allele. (D) Southern blotting was used to confirm the ITR1 disruptions. 
Lane 1 (wild-type); lane 2 (itr1Δ::SAT1-FLP/ITR1); lane 3 (itr1Δ/ITR1); lane 4 
(itr1Δ/Δ::SAT1-FLP); lane 5 (itr1Δ/Δ); lane 6 (itr1Δ/Δ::ITR1-SAT1); lane 7 (ino1∆/∆ 
itr1∆/PMET3::ITR1). The itr1∆::SAT1-FLP band (disrupted allele prior to “flipping out” 
the SAT1-FLP construct) and itr1∆/itr1∆ ::ITR1-SAT1 band (reintegrated ITR1 marked 
with SAT1) ran together on the gel. (E) Northern blotting revealed that the expression of 
ITR1 was lost in the itr1∆/itr1∆ mutant, but not the wild-type, heterozygous, and 
reconstituted strains. Strains were grown in defined medium 199 for 2hrs at 37°C, and 
RNA was isolated, Northern blotted, and probed for ITR1 expression.  ITR1 expression 











Fig 2- 3. The ITR1 gene is required for inositol transport in C. albicans.  
The inositol uptake assay revealed that the ability to import 3H-myo-inositol was greatly 
reduced in the itr1∆/itr1∆ mutant, whereas the wild-type, heterozygous, and reconstituted 
strains exhibited the ability to import inositol.  Each strain was assayed at 0̊ C (white bars) 

























Fig 2- 4. The INO1 and ITR1 genes show synthetic defects in growth on agar plates.  
The growth of wild-type, ino1∆/∆ itr1∆/ITR1, and two separately derived ino1∆/∆ 
itr1∆/PMET3::ITR1 strains were compared in 5-fold serial dilutions on minimal medium 






















Fig 2- 5. The INO1 and ITR1 genes show synthetic defects in virulence.  
The survival of mice was monitored following intravenous challenge with 106 C. 
albicans blastospores. (A) Mice were injected with INO1 mutant strains. Wild-type 
(n=10); ino1∆/∆ (YLC113, n=10); ino1∆/∆ (YLC126, n=11); ino1∆/∆::INO1 (n=10). (B) 
Mice were injected with ITR1 mutant strains. Wild-type (n=5); itr1∆/ITR1 (n=5); itr1∆/∆ 
(n=10); itr1∆/∆::ITR1 (n=6). (C) Mice were injected with ino1∆/∆ itr1Δ/PMET3::ITR1 
conditional double mutant strains. Wild-type (n=10); ino1∆/∆ itr1∆/ITR1 (n=10); 
ino1∆/∆ itr1∆/PMET3::ITR1 (YLC261, n=10); ino1∆/∆ itr1∆/PMET3::ITR1 (YLC266, n=10). 
Strains for experiments A and B were pre-grown in YPD before the injection while 
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            Candida albicans is one of the most commonly isolated human fungal pathogens, 
especially in immunocompromised patients. There are only a few effective antifungals 
available to treat fungal infections, creating an urgent need to identify new drug targets. 
The S. cerevisiae phosphatidylserine (PS) synthase, Cho1p, is required for PS synthesis, 
and is conserved in fungi, but not mammals. We have found that a C. albicans 
cho1∆/cho1∆ mutant lacks detectable PS, and is completely avirulent in a mouse model 
of systemic candidiasis. The cho1∆/cho1∆ mutant also exhibits defects in cell wall 
integrity, mitochondrial function, and filamentous growth, and it is an ethanolamine and 
choline auxotroph. However, its growth in choline supplemented media is extremely poor, 
with a doubling time of ~36 hours. PS is a precursor for the de novo synthesis of 
phosphatidylethanolamine (PE) via PS decarboxylase, and it was hypothesized that some 
of the cho1∆/cho1∆ mutant’s defects might be due to loss of de novo PE biosynthesis. A 
psd1∆/psd1∆ psd2∆/psd2∆ double mutant, which lacks PS decarboxylase activity, was 
found to exhibit defects in cell wall integrity, mitochondrial function, filamentous growth, 
and virulence. However, for all of these phenotypes except filamentous growth, the 
psd1∆/psd1∆ psd2∆/psd2∆ mutant was not as defective as the cho1∆/cho1∆ mutant. In 
addition, the psd1∆/psd1∆ psd2∆/psd2∆ mutant’s growth in minimal media was rescued 
similarly with 1 mM ethanolamine or 10 µM choline. The severe virulence defect of the 
cho1∆/cho1∆ mutant is likely due, in part, to a loss of de novo PE biosynthesis, but loss 
of PS itself contributes to this phenotype as well. We predict that C. albicans PS synthase 

















 The incidence of human systemic fungal infections has increased dramatically in 
the last thirty years.  This is based, in part, on an increase in the number of 
immunocompromised patients due to conditions such as acquired immunodeficiency 
syndrome (AIDS), cancer-related chemotherapy, and leukemia (20, 65). Candida species 
are the leading cause of fungal infections in humans and can cause mucosal, cutaneous, 
and bloodstream infections. Bloodstream infections are of the greatest concern with a 
high associated mortality rate (31.8%) (116).  
 There are only five main types of antifungals used to combat Candida infections, 
and a number of these drugs are limited by emerging drug resistance or toxicity to the 
patient (43). Therefore, there is an urgent need to identify new targets for development of 
antifungal agents. The lipid ergosterol has served as a very potent drug target in fungi, 
and three of the major classes of antifungals work by targeting ergosterol or ergosterol 
biosynthesis (43). In particular, the azole and allylamine classes affect ergosterol 
biosynthesis (12, 53), and the polyenes target ergosterol in the membrane (46). The key to 
the effectiveness of these drugs is that their targets are not conserved in the host.   
 Phospholipid biosynthesis is an emerging area in which to look for novel drug 
targets in a number of pathogens. Although similar phospholipids are found in mammals, 
bacteria, protozoans, and fungi (81), the enzymes involved in synthesizing some 
phospholipids are not conserved between pathogens and mammals. Some of these 
nonconserved enzymes may serve as useful drug targets if they are required for growth or 
virulence in the host. In the fungal pathogen Cryptococcus neoformans, inositol-
phosphoryl ceramide synthase 1 (IPC1) is required for sphingolipid metabolism. This 
enzyme is essential for virulence in a rabbit model of infection (102).  In the bacterial 
pathogen Brucella abortus, the enzymes PcsA or PmtA, both required for 
phosphatidylcholine (PC) biosythesis, are necessary for virulence in BALB/c mice (30). 
Similarly, phosphatidylethanolamine (PE) biosynthesis in B. abortus, which is dependent 
on the phosphatidylserine (PS) synthase (PssA), is required for optimal virulence in a 
murine model (18). In the parasite Plasmodium falciparum, a potential novel anti-
malarial drug target was identified: serine decarboxylase phosphoethanolamine 
methyltransferase (SDPM) encoded by PfPMT gene.  This enzyme methylates 
phosphoethanolamine (Etn-P) to form phosphocholine (Cho-P), and is required for PC 
synthesis in P. falciparum. A pfpmt∆ mutant exhibits defects in parasite growth and 




intraerythrocytic Plasmodium parasites (182).  
 Little research has concentrated on the roles of phospholipid biosynthesis in the 
pathogenesis of C. albicans. It has been demonstrated that phospholipomannan, a fungal 
mannose inositol phosphate ceramide (MIPC) derived from phospholipids, is required for 
virulence in a mouse model of systemic infection (115). In addition, the sphingolipid 
biosynthetic gene IPT1 is required for C. albicans to undergo hyphal formation, a 
virulence factor, in laboratory culture conditions, but its role in virulence in an animal 
model has not been examined (142).  
 A comparison of the basic pathways for phospholipid biosynthesis between the 
well-characterized yeast S. cerevisiae and mammals has revealed a potential target that is 
conserved in fungi (81). Although phospholipid biosynthetic pathways in mammals and 
yeast share many general characteristics in common, a major difference is found in the 
synthesis of PS (Fig 3-1). In yeast PS is synthesized from cytidyldiphosphate-
diacylglycerol (CDP-DAG) and serine by the enzyme ScCho1p, with the associated 
release of cytidylmonophosphate (CMP) (92). In mammals, a very different pair of 
enzymes, encoded by PSS1 and PSS2, generate PS by exchanging serine for the head 
groups of PC and PE, respectively (9, 160, 162). The Cho1p enzyme was among a 
number of enzymes on a comprehensive list of proteins that are conserved among fungi, 
but not found in mammals, and is, therefore, considered a potential drug target (16).  
        PS is normally asymmetrically distributed to the cytoplasmic side of the 
membrane bilayer in eukaryotic cells (170). PS is also considered both an end product 
and a biosynthetic intermediate, since it is found in eukaryotic cell membranes and serves 
as a precursor of PE (81)(Fig 3-1). The first description of PS synthesis mutants in 
eukaryotic cells (S. cerevisiae) was 30 years ago. Atkinson and colleagues demonstrated 
that Sccho1 mutants were unable to synthesize PS and were auxotrophic for choline or 
ethanolamine (4, 5). The enzyme responsible for PS synthesis, and the gene encoding it, 
were later isolated (92). The PS synthesis mutant (Sccho1Δ) exhibited slow growth on 
nonfermentable carbon sources, mitochondrial abnormalities, and the formation of a high 
proportion of petite (respiratory-deficient) cells at lower temperatures (5). Interestingly, a 
mutant in the conserved PS synthase of fission yeast Schizosaccharomyces pombe (pps1Δ) 
was recently demonstrated to have divergent phenotypes including defects in cell 
morphology, cytokinesis, actin cytoskeleton, and cell wall integrity. In addition to those 
defects, the pps1Δ mutant is auxotrophic for ethanolamine, but cannot be supported by 




PS is clearly not necessary for viability in either of these fungi, however if its homolog is 
necessary for virulence or growth of C. albicans in the host, then CaCho1p may be a 
good drug target.   
        In this report we describe that the cho1Δ/cho1Δ mutant in C. albicans is avirulent 
in a mouse model of systemic candidiasis.  In addition, the mutant exhibits overlapping, 
but distinct phenotypes with PS synthase mutants in S. cerevisiae and S. pombe. The C. 
albicans cho1Δ/cho1Δ mutant exhibits defects in cell wall integrity, mitochondrial 
function, and is very poorly rescued for growth by supplementation with choline. It is 
further demonstrated that many of the defects in the cho1∆/cho1∆ mutant are attributable 
to a loss of de novo PE biosythesis, but that the loss of PS itself appears to exacerbate 
these problems. This study indicates that C. albicans PS synthase is absolutely necessary 
for growth in the host and therefore represents a new potential drug target.  
MATERIAL AND METHODS 
Strains, chemicals, and growth media 
 C. albicans strains used in this study are shown in Table S3-1 (see all tables and 
figures in the appendix B). The following media were used in this study: 1% yeast 
extract-2% peptone-2% glucose (YPD) liquid media and agar plates. YPD plates 
containing 250μg/ml nourseothricin was used to select for disruptants. Ethanolamine-free 
medium was made using the recipe for inositol-free minimal medium and then adding 
back 75μM inositol (163).  The following supplements, Cyclosporin A (Alexis Biochem), 
FK506 (Tecoland), Paraquat (Sigma), Bovine calf serum (HyClone),  Fluconazole (AB 
Biodisk), Amphotericin B (Fisher), Hygromycin B (Sigma), Nikkomycin Z (Sigma), 
Sodium dodecyl sulfate (SDS; Fisher), Caffeine (Acros Organics), Congo Red (ICN 
Biochemicals), Calcofluor white (Polysciences), Cyclophosphamide monohydrate 
(Sigma), or Papuamide B (gift from Todd Graham, Vanderbilt University, TN) were 
added to media at the concentrations described.  
        The phospholipid standards: phosphatidylserine (#830034), 
phosphatidylethanolamine (#850757), phosphatidylinositol (#840042), and 
phosphatidylcholine (#850457) were purchased from Avanti Polar Lipids Inc. or provided 
by Stephen Wright (Carson-Newman College, TN).  Ethanolamine and choline chloride 
were purchased from Acros Organics Inc., and Fisher, respectively. Trypan blue & Eosin 
Y indicator plates for the mitochondrial dysfunction test included 0.15g KH2PO4, 0.15g 




eosin Y, 1mg trypan blue, and 1.5g agar in 100ml H2O (62, 120). 
Strain construction 
        The first allele of the CHO1 gene was disrupted by using the CaNAT1-FLP 
cassette (154), whereas its second allele was disrupted by using the SAT1 flipper (143). 
The PSD1 and PSD2 genes were disrupted by using the SAT1 flipper.   
 For the CHO1 disruption construct, an approximately 500-bp 5’ upstream 
noncoding region (NCR) of CHO1 (5’ CHO1NCR) was amplified with primers JCO43 and 
JCO44 (Table S3-3), which introduced KpnI and ApaI restriction sites, and was cloned 
into pJK863 (154), 5’ of the CaNAT1-FLP cassette using the same enzymes (Fig 3-2A). 
An approximately 500-bp 3’ CHO1NCR was amplified with primers JCO45 and JCO46, 
which introduced SacII and SacI sites, and was cloned into pJK863 3’ of the CaNAT1-
FLP cassette using the same enzymes (Fig 3-2A). This procedure created the CHO1 
knock out construct plasmid pYLC130 (Table S3-2; Fig 3-2A), which was cut with KpnI 
and SacI to release the ~ 5.2kb disruption construct, and the wild type SC5314 strain was 
transformed with the disruption construct by electroporation (36). The CaNAT1 construct 
could not be flipped out from cho1Δ/cho1Δ::NAT1-FLP strains  due to the homozygote 
being unable to grow sufficiently in the Yeast Carbon Base-Bovine Serum Albumin 
(YCB-BSA) medium used to induce the SAP2 promoter that drives the FLP recombinase 
on the CaNAT1-FLP cassette (154). We therefore used a similar cloning strategy as 
described above to clone 5’- and 3’- CHO1NCR  into the SAT1 flipper (pSFS2A) (143), 
resulting in pYLC326 (Table S3-2; Fig 3-2A).  See Table S3-3 for appropriate primers, 
restriction sites, etc.  The disruption construct on pYLC326 was used to disrupt the 
second allele of CHO1 in the cho1∆/CHO1 heterozygote, and it was flipped out easily 
because the homozygote could grow quite well in YPD induction medium (143). The 
CHO1 reconstitution construct was made by amplifying a 1.3kb fragment containing the 
CHO1 open reading frame (ORF) and the 5’ NCR from SC5314 genomic DNA by using 
primers (JCO43 and JCO169) that introduced KpnI and HindIII sites. This fragment was 
ligated into the KpnI-HindIII digested pYLC326 which already contained the 
3’CHO1NCR. This procedure resulted in the CHO1 reconstitution plasmid pYLC341 
(Table S3-2; Fig 3-2B).  
 We used a similar approach to knock out PSD1 and PSD2 genes, but only the 
SAT1 flipper was used. The primers used to generate each disruption construct are listed 
in Table S3-3.  The psd1Δ/psd1Δ psd2Δ/psd2Δ double mutant (YLC375) was made by 




Southern blot analysis 
 The cells were grown in liquid YPD at 30ºC overnight. The genomic DNA was 
extracted using the Winston-Hoffman method (70), and 20μg of genomic DNA was 
subjected to Southern blotting. The genomic DNA of cho1∆/cho1∆ and psd1Δ/psd1∆ 
mutants were cut with XhoI, while the genomic DNA of the psd2Δ/psd2∆ mutant was cut 
with BamHI. PCR products containing the ~500-bp 3’CHO1NCR (amplified with primers 
JCO45 and JCO46), the 3’ PSD1NCR (amplified with primers JCO143 and JCO144), and 
the 3’ PSD2NCR (amplified with primers JCO148 and JCO149) were used as probes. 
Hybridization conditions were described previously (25).  
Phospholipid composition assay 
 The wild-type and phospholipid biosynthetic mutants were grown in shaking YPD 
liquid cultures overnight at 30ºC. Cells were washed twice in sterile water and diluted in 
5ml YPD containing 5μCi/ml [32P]-phosphoric acid (MP biomedicals) to an OD600 of 0.4 
and grown for 3h at 37ºC at 250 rpm. Cells were harvested by centrifugation, washed 
with water, and transferred to screw-capped glass tubes (Corning, 16x100mm). The 
simple and efficient phospholipid extraction was adapted, in part, from the protocol of 
Hanson and Lester (64). In brief, 3ml of ethanol/H2O (4:1) was added to the cell pellets 
and heated in a boiling water bath for 15 minutes. After centrifugation in a table top 
centrifuge (1000 x g), the supernatants containing radiolabeled phospholipids were 
transferred to fresh screw-capped glass tubes. The remaining cell pellets were extracted 
two additional times, using 1ml of ethanol/H2O (4:1) for each extraction. All supernatants 
(~ 5ml) were pooled, and N2 gas was used to dry down the phospholipids, which were 
then resuspended in 50μl of chloroform/methanol (2:1).  
            The individual phospholipids were resolved using one-dimensional silica gel thin-
layer chromatography (TLC) plates (Whatman). The TLC plate was first incubated in the 
oven at 100ºC for 15 min, then prewashed (removing debris) thoroughly by 
chloroform/methanol (1:1) through migration on the TLC. The prewashed TLC plate was 
dried in the hood for 5 min and then baked in the oven at 100ºC for 15 min. Two µl of 
extracted radiolabeled phospholipids were spotted on the TLC plate and developed in 
cold chloroform/ethanol/water/triethylamine (30:35:7:35). The phospholipids were 
detected and quantitated with a Storm PhosphoImager.  
 The identity of phospholipids was determined by running the samples with 
phospholipid standards PS, PE, PC, and PI, and by mass spectrometry. The primuline 




visualize the lipid spots under UV light.  
Mouse infection studies 
 Five- to 6-week-old male ICR mice (~ 20g) from Harlan Sprague Dawley were 
used in this study. Mice were housed in groups of five per cage. For infection, colonies 
from each C. albicans strain were inoculated into 5ml of YPD. Cultures were grown 
overnight and washed twice with 10ml of sterile water, and cells were counted by 
hemacytometer and resuspended in sterile water at 107 cells per ml. Dilutions of the cells 
were plated onto YPD containing 1M sorbitol and incubated at 37ºC for 48h to determine 
viability. Mice were injected via the lateral tail vein with 0.1ml of the cell suspension (106 
cells), and the course of infection was monitored for up to 42 days. Survival was 
monitored twice daily, and moribund mice were euthanized. All experimental procedures 
were carried out according to the NIH guidelines for the ethical treatment of animals.  
 For the immunocompromised mouse model, five- to 6-week-old male ICR mice 
(~ 20g) from Harlan Sprague Dawley were intraperitoneally injected with 150mg/kg 
cyclophosphamide 5 days and 1 day prior to tail-vein injection with C. albicans 
blastospores. The cho1Δ/cho1Δ mutants were injected at 106 cells, while the wild type, 
psd1Δ/psd1Δ, and psd1Δ/psd1Δ psd2Δ/psd2Δ double mutants were injected at 104 cells 
each (100-fold less than the cho1Δ/cho1Δ mutant). The 100mg/kg cyclophosphamide 
treatments were continued by injecting the mice every four days until the experiment was 
terminated. 
            For fungal burden analysis, the kidneys were dissected at day 5 in 
immunocompetent and at day 4 in immunocompromised mice in order to determine 
fungal burden. The kidneys were weighed, crushed, serial diluted in sterile water, and 
plated onto YPD containing 1M sorbitol. The plates were incubated at 37ºC for 48h to 
determine CFU per gram of kidney. For histopathological analysis, the kidneys were 
excised, halved longitudinally, fixed in 10% phosphate-buffered formalin (Fisher), 
embedded, sectioned with a Ridge microtome (Knoxville, TN), and stained with Gomori 
methenamine silver (GMS) or hematoxylin and eosin (H&E) by standard protocols.  
Growth curve measurement 
 Overnight cultures were washed twice, diluted in YPD to 0.4 OD600/ml  and 
grown for 3h at 30 ºC. The log-phase cells were then collected, washed twice, and diluted 
into Etn/Cho-free medium supplemented with indicated concentrations of Etn or Cho at  
0.1 OD600/ml for growth at 37 ºC with shaking at 250 rpm.  The media was buffered to 




higher concentrations of Etn were added since Etn is basic and otherwise induces hyphal 
growth. The cell concentration was measured with a spectrophotometer at OD600 at 0, 2, 4, 
6, 8, and 24 hours. Afterwards, the concentrations were measured daily for up to 14 days. 
Susceptibility to paraquat 
 For spot dilution tests overnight cultures were washed twice with water, five-fold 
diluted, and spotted onto YPD agar plates with or without 10mM paraquat, and grown at 
37ºC for 48h. For the quantitative viability test, the cells in liquid culture were diluted 
and spotted at ~ 200 cells per plate onto YPD agar plates containing 0, 2, 4, 6, 8, or 
10mM paraquat and cultured at 37ºC for 24 ~ 48h. The survival percentage was 
calculated by the formula: (CFU of YPD containing paraquat) / (CFU of YPD). 
Transmission electron microscopy 
 Cells growing at log phase were harvested and fixed for electron microscopy 
using a modification of a protocol by Wright (183). After harvesting the cells they were 
suspended in the primary fixative consisting of 3% glutaraldehyde and 3% 
paraformaldehyde in 0.1M phosphate buffer. After five minutes the cells were centrifuged, 
then re-suspended in fresh fixative overnight at 4ºC. After primary fixation the cells were 
washed in 0.1M phosphate buffer for 10 minutes three times. Cells were washed in 1% 
KMnO4 for 5 minutes, centrifuged, and re-suspended in fresh KMnO4 for an additional 
90 minutes. Cells were then washed in water for 10 minutes three times, and en-bloc 
stained in 1% aqueous uranyl acetate for 60 minutes. Cells were washed in water for 10 
minutes three times, and dehydrated in a graded ethanol series at 15 minute intervals. 
Final dehydration was accomplished with two changes in fresh 100% ethanol. Cells were 
infiltrated with gradually increasing ratios of Spurr resin/ethanol over a 24 hour period. 
The final four hours of incubation were in 100% Spurr resin under vacuum. After 
changing to fresh Spurr resin, samples were placed in a 68 ºC oven for 24 hours. Thin 
sections were cut with a Reichert OMU3 ultramicrotome, mounted on copper grids, 
stained with lead citrate, and examined with a Hitachi H800 transmission electron 
microscope operating at 75KeV.   
Identification of phosphatidylserine by electrospray mass spectrometry 
        The putative PS spot was scraped from the wild type lane on a TLC plate 
(Primuline spray and UV light were applied to visualize lipid spots). The scraped powder 
containing the putative PS spot was mixed with 4 ml of Chloroform:Methanol:Water 
(5:5:1) in the screw-capped glass tube, vortexed, and incubated on ice for 5 min. After 




in a fresh glass tube and dried under N2 gas. Fifty μl of chloroform was used to resuspend 
the dried PS. The eluted putative PS was initially confirmed by running one dimensional 
TLC along with PS standard, then identified by electrospray mass spectrometry. Negative 
electrospray mass spectra were obtained from an ion-trap mass spectrometer (LCQ Deca 
XP Plus, ThermoElectronic Corp.) by direct infusion of PS samples into electrospray 
ionization (ESI) source at a flow rate of 5 µl/min. The capillary temperature was 
maintained at 150ºC. The optimized ESI source conditions listed as follow: -4 V for the 
capillary voltage, 4.5 kV for the spray voltage, and 30 V for the tube lens offset. Nitrogen 
was used as sheath gas at 5 arbitrary units. 
Statistical analysis 
 This was done using Prism 4.0 software (GraphPad Software). For the mouse 
model of systemic infection, Kaplan-Meier survival curves were compared for 
significance by using the Mantel-Haenszel log rank test. The significance of differences 
in phospholipid composition, fungal burden, growth curve, paraquat susceptibility, and 
cell wall thickness between strains was determined using the two-tailed unpaired t test. 
Statistical significance was set at a P value of <0.05. 
RESULTS 
CHO1 is required for phosphatidylserine synthesis in C. albicans 
             A C. albicans homolog of the S. cerevisiae phosphatidylserine (PS) synthase gene 
(CaCHO1, hereinafter referred to as CHO1) was identified by BLASTing the ScCho1p 
protein sequence against the Candida Genome Database (CGD, 
http://www.candidagenome.org). This search revealed that C. albicans orf19.677 encodes 
the closest homolog of ScCho1p, and these proteins share 61% amino acid identity. 
            The first allele of the CHO1 gene was disrupted by replacing the ORF with the 
nourseothricin resistance cassette, CaNAT1-FLP (154). We were unable to obtain a 
cho1∆/cho1∆ homozygous mutant in which CaNAT1-FLP was excised from the second 
disrupted allele of the cho1∆/cho1∆::NAT1-FLP strain.  This was because the 
homozygote could not grow in the nutrient poor medium (YCB-BSA) required to drive 
FLP recombinase expression from SAP2 promoter on this cassette (154). Therefore, the 
second allele of the CHO1 gene was disrupted using another nourseothricin resistance 
cassette (SAT1 flipper) where FLP recombinase expression is driven by the leaky 
CaMAL2 promoter (143) even in YPD medium. The cho1∆ disruption constructs are 




using the reconstitution construct shown in Fig 3-2B. Gene deletions and replacements 
were checked for accuracy using PCR (data not shown) and Southern blotting (Fig 3-2C).  
            In order to determine if the CHO1 gene product serves as the C. albicans PS 
synthase, we tested to see if the cho1∆/cho1∆ mutant failed to generate PS as is seen in a 
S. cerevisiae Sccho1∆ mutant (4). Phospholipids were in vivo labeled with 32P-phosphoric 
acid, extracted using boiling ethanol:water (4:1) (64), separated by thin layer 
chromatography (TLC), and visualized by autoradiography with a phosphorimager (Fig 
3-2D). A spot from the wild-type strain, that comigrates with the PS standard, was 
missing in the cho1Δ/cho1Δ mutant.  This spot, which is found in both the wild-type and 
cho1∆/cho1∆::CHO1 reconstituted strain was confirmed to represent PS by mass 
spectrometry.  The spots representing the PS standard and PS from the wild-type strain 
were both eluted from the TLC plate and examined by mass spectrometry.  Mass peaks 
were observed at 760.85 and 760.69 for the spots representing the PS standard and the 
putative wild-type PS, respectively, indicating that the spot in question did represent C. 
albicans PS (data not shown).  Quantification of the phospholipid spots from TLC plates 
(representative shown in Fig 3-2D) revealed that the radioactivity associated with the PS 
spot in the cho1∆/cho1∆ mutant was only 3% that found in the wild-type strain (Table 3-
1).  This is very similar to the reduction in PS production measured in Sccho1∆ mutants 
in S. cerevisiae (92) and is equal to background levels (Table 3-1). As a further test for 
the role of CHO1 in making PS in C. albicans, the mutant and wild-type strains were 
tested for their resistance to Papuamide B.  Papuamide B is a a cytotoxic lipopeptide that 
binds PS, and in S. cerevisiae, a genetic screen revealed that the Sccho1∆ mutant, which 
lacks PS, is resistant to Papuamide B (137).  The C. albicans cho1∆/cho1∆ mutant is 
resistant to Papuamide B, while the wild-type and CHO1 reconstituted strains are 
sensitive (Fig 3-2E), further indicating that CHO1 encodes the C. albicans PS synthase. 
 The CHO1 gene is essential for virulence 
            The virulence of the cho1Δ/cho1Δ mutant was tested in a mouse model of 
systemic candidiasis. Outbred ICR mice (Harlan) were injected with 106 blastospores via 
the lateral tail vein and monitored for signs of infection.  It was found that cho1Δ/cho1Δ 
mutants are avirulent, whereas the wild type, cho1Δ/CHO1 (data not shown), and 
cho1Δ/cho1Δ::CHO1 reconstituted strains exhibited full virulence (Fig 3-3A). The 
difference in virulence was reflected in mouse fungal burdens measured at day 5 by 
examination of the kidneys (Fig 3-3C). The fungal burden of cho1Δ/cho1Δ mutants was 




mutant exhibiting (110±2) x 103 CFU/g of kidney (P<0.0001). Similar survival curves 
and fungal burdens were observed in mice that were immunocompromised with 
cyclophosphamide.  In this case, the mice were injected with 100-fold more blastospores 
(106) of cho1Δ/cho1Δ mutants than wild type (104).  The cho1Δ/cho1Δ mutant was 
avirulent under these conditions as well (Fig S3-1), and by day 14, the mice, despite 
being immunocompromised, had cleared the cho1∆/cho1∆ mutant from the kidneys, as 
no CFUs could be detected (data not shown).  
            Histological examination of the kidneys revealed that cho1∆/cho1∆ mutant cells 
or hyphae were not observable in the kidneys by Gomori Methenamine Silver (GMS) 
staining and there was no detectable damage to kidney tissue (H&E staining after 5d 
infection). In contrast, in mice infected with wild type C. albicans, hyphae were readily 
observed in the kidney and caused considerable necrosis at microscopic (Fig 3-4) and 
macroscopic levels (Fig S3-1C). 
The cho1Δ/cho1Δ  mutant exhibits ethanolamine auxotrophy and very poor growth 
in choline 
            The S. cerevisiae Sccho1∆ mutant is an ethanolamine (Etn) auxotroph because it 
lacks PS, which serves as a substrate for the de novo synthesis of 
phosphatidylethanolamine (PE).  In the de novo synthesis pathway PS is decarboxylated 
to PE by two different PS decarboxylase enzymes named ScPsd1p and ScPsd2p (Fig 3-1).  
The Sccho1∆ mutant is only able to grow if Etn or Cho are exogenously supplied. The 
mutant can make PE via the Etn branch of the Kennedy pathway, and PC by methylating 
PE via the de novo pathway (Fig 3-1).  Alternatively, if supplied with Cho, the Sccho1∆ 
mutant can make PC by the Cho branch of the Kennedy pathway, and PE by deriving 
phosphoethanolamine (Etn-P) from dihydrosphingosine (DHS) via the DPL1 salvage 
pathway (Fig 3-1).  However, the ability to use Cho alone is dependent on growth on a 
fermentable carbon source.  Growth on a non-fermentable carbon source can only be 
supported with Etn in the media due to an increased requirement for mitochondrial 
respiration (13). Mitochondria are enriched in PE, and PE is important for full 
mitochondrial respiratory function (13, 56, 173).  
            The cho1Δ/cho1Δ mutant is an ethanolamine auxotroph, like the Sccho1∆ mutant 
(Fig 3-5A&B), and shows a reduction in its PE level (Table 3-1). Even in medium 
containing 1 mM Etn, the cho1∆/cho1∆ mutant did not grow as well as the wild-type (Fig 
3-5B), and the doubling time calculated for the wild-type and cho1∆/cho1∆ strains was 




could not be rescued on plates by addition of Cho alone to the medium (Fig 3-5A), even 
on a fermentable carbon source (glucose).  In liquid medium containing Cho alone, there 
was no rescue of growth in the first 8 hours of a growth curve, but by 24 hours, there was 
some modest growth that eventually became more substantial, but never approached that 
of wild-type (Fig 3-5C). The calculated doubling times for the wild-type and 
cho1∆/cho1∆ strains in the Cho supplemented medium were ~1.5 hours and ~36 hours, 
respectively (Table 3-2).  Thus, Cho supplementation allows very little growth in this 
mutant. Addition of 100 fold higher levels of Cho (1mM) rescued the mutants only 
slightly better than the 10µM shown (Fig 3-5C, and data not shown). 
Mutations in PS decarboxylase genes synthesis lead to ethanolamine or choline 
auxotrophy 
            The above results suggested the possibility that the cho1∆/cho1∆ mutant’s 
virulence and growth defects were primarily due to a block in the de novo synthesis of PE 
by PS decarboxylase activity (Fig 3-1).  In order to test this hypothesis, the homologs of 
the two S. cerevisiae PS decarboxylase genes ScPSD1 and ScPSD2 were identified by 
BLAST searches of their protein sequences against CGD.  These homologs, orf19.6045 
(CaPSD1, hereinafter called PSD1) and orf19.3954 (CaPSD2, hereinafter called PSD2) 
were disrupted using the SAT1 flipper and their genotypes confirmed by PCR (data not 
shown) and Southern blot (Fig S3-2).  Reconstituted strains were created for each of 
these genes as well.  
            The psd1∆/psd1∆ was found to grow poorly without exogenous Etn (Fig 3-5A), 
and it showed a reduction in growth compared to wild-type even when supplemented 
with exogenous Etn, although it grew better than the cho1∆/cho1∆ mutant in both liquid 
and solid media (Fig 3-5A&B and Table 3-2).  The wild-type and psd1∆/psd1∆ mutants 
had doubling times of ~1.6 hours and ~2.0 hours in Etn supplemented media, respectively 
(Table 3-2). PE production in the psd1∆/psd1∆ mutant was reduced, as it produced only 
77% as much as the wild-type strain (Table 3-1)(P=0.005).  However, this is higher than 
in the cho1∆/cho1∆ mutant, which produced only 60% as much PE as wild-type strain 
(Table 3-1). The psd2∆/psd2∆ mutant, in contrast, behaved like wild-type for these 
phenotypes (Fig 3-5A and data not shown).  The psd1∆/psd1∆ mutant grew much better 
than the cho1∆/cho1∆ mutant in media supplemented only with Cho, even in the earlier 
parts of the growth curve, although it again grew more slowly than wild-type (Fig 3-
5A&C). The doubling time for the psd1∆/psd1∆ mutant in this medium was ~2.0 hours 




 Although the psd2∆/psd2∆ mutant did not show auxotrophic or growth 
phenotypes, the PSD2 gene does appear to affect these phenotypes as a psd1Δ/psd1Δ 
psd2Δ/psd2Δ double mutant was more defective for growth than the psd1∆/psd1∆ mutant 
in the presence of Cho or Etn (Fig 3-5A-C). The doubling time of the psd1∆/psd1∆ 
psd2∆/psd2∆ mutant was ~2.3 hours in both types of media (Table 3-2). This phenotype 
correlated with a decreased level of PE, as PE in the psd1Δ/psd1Δ psd2Δ/psd2Δ double 
mutant was 55% the level of wild-type as compared with 77% in the psd1Δ/psd1Δ single 
mutant (Table 3-1).  The level observed in the psd1∆/psd1∆ psd2∆/psd2∆ double mutant 
is similar to that seen in the cho1∆/cho1∆ mutant (Table 3-1). Interestingly, the PS level 
was increased ~two-fold in psd1Δ/psd1Δ psd2Δ/psd2Δ double mutant as compared with 
that of wild-type (Table 3-1) (P=0.003). The behavior of the psd1∆/psd1∆ psd2∆/psd2∆ 
double mutant was somewhat complex compared to the cho1∆/cho1∆ mutant when 
growing in medium supplemented with Etn or Cho.  In liquid medium supplemented with 
Etn or Cho the double mutant had a faster doubling time than the cho1∆/cho1∆ mutant 
(Fig 3-5B,C and Table 3-2).  However, the double mutant exhibited similar growth 
defects to the cho1∆/cho1∆ mutant on agar plates supplemented with Etn or Cho (Fig 3-
5A).  
PS decarboxylase genes PSD1 and PSD2 are synthetically required for virulence 
            Although the psd1∆/psd1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants differed in 
some respects from the cho1∆/cho1∆ mutants, they exhibited a number of similarities 
which suggested that these mutants might affect virulence in the mouse model of 
systemic candidiasis. Therefore, mice were challenged with 106 blastospores of the 
psd1Δ/psd1Δ or psd2∆/psd2∆ single mutants or the psd1Δ/psd1Δ psd2Δ/psd2Δ double 
mutant as previously described. The psd1Δ/psd1Δ and psd2∆/psd2∆ mutants were fully 
virulent and behaved like wild-type (Fig 3-3B).  In contrast, the psd1Δ/psd1Δ 
psd2Δ/psd2Δ double mutant exhibited very attenuated virulence (Fig 3-3B), although it 
was more virulent than the cho1∆/cho1∆ mutant as a few mice infected with the double 
mutant did succumb to infection whereas no mice infected with the cho1∆/cho1∆ mutant 
showed any symptoms of disease (Fig 3-3A).  This difference in virulence was reflected 
in a two-fold larger fungal burden in the psd1Δ/psd1Δ psd2Δ/psd2Δ double mutant [(15±
0.5) x 103 CFU/g of kidney] compared to the cho1∆/cho1∆ mutant [(7±3) x 103 CFU/g of 
kidney] (Fig 3-3C). This difference was not statistically significant, however, a similar 
difference was also seen in the cyclophosphamide treated mice (Fig S3-1).  In addition, 




mice infected with the psd1∆/psd1∆ psd2∆/psd2∆ mutant (Fig 3-4). There was also no 
sign of infection observed in the kidneys from immunocompromised mice when 
examined macroscopically (Fig S3-1C).   
            Although the psd1∆/psd1∆ mutant exhibited no difference from wild-type in 
virulence as measured by the time it took for mice to succumb to the infection (Fig 3-3B), 
there was a statistically significant increase in the number of CFU/g of kidney of the 
psd1∆/psd1∆ mutant compared to the wild-type strain (P<0.0001, Fig 3-3C).   
Defects in PE and PS biosynthesis result in mitochondrial respiration defects  
            In S. cerevisiae, the loss of PS or PE biosynthesis leads to an increase in the 
formation of petite mutants, which are mutants in which the mitochondrial genome has 
been lost or the mutants exhibit mitochondrial respiration defects.  The increase in petite 
formation appears to be due to the fact that mitochondria are enriched for PE, and the 
major site of de novo PE synthesis is the inner mitochondrial membrane where ScPsd1p 
converts PS to PE.  PE is necessary for proper mitochondrial function, and a large 
decrease in PE levels correlates with mitochondrial defects and petite formation (5, 13, 
28). It was suspected that the mitochondrial respiratory function in the C. albicans 
cho1∆/cho1∆ mutant might be compromised.  C. albicans is a non-petite forming yeast, 
meaning that it cannot survive without an intact mitochondrial genome (3), and defects in 
PE or PS biosynthesis may compromise mitochondrial respiration. In order to test this, 
the mutants were examined for sensitivity to paraquat. Paraquat is a herbicide that 
generates superoxide radicals and oxidative damage in the mitochondria based on its 
interactions with complex I and/or alternative NAD(P)H dehydrogenases in the electron 
transport chain (29). In S. cerevisiae, mutants that are defective for mitochondrial 
respiration show enhanced resistance to paraquat due to decreased electron transport 
chain activity (14).  In addition, a C. albicans mutant that exhibits decoupling of 
oxidative phosphorylation is also more resistant to paraquat (26).  Therefore, we 
examined the cho1∆/cho1∆, psd1∆/psd1∆, and psd1∆/psd1∆ psd2∆/psd2∆ mutants for 
paraquat resistance. All three mutants were clearly more resistant to paraquat based on an 
agar dilution assay on plates containing 10 mM paraquat (Fig 3-6A).  The psd1∆/psd1∆ 
psd2∆/psd2∆ mutants did not grow as well as the single mutants on paraquat plates, but 
this mutant exhibits poorer growth than that of the single mutants on regular YPD plates, 
and it grew better than the wild-type on the paraquat plate (Fig 3-6A). The mutants were 
also examined by a more quantitative assay in which cells were pregrown in liquid YPD 




10 mM paraquat.  The number of colony forming units was then examined.  It was found 
that the cho1∆/cho1∆ and psd1∆/psd1∆ mutants exhibited a quantitatively similar 
resistance to paraquat (Fig 3-6B).  The psd1∆/psd1∆ psd2∆/psd2∆ double mutant was not 
very resistant based on this assay, but that may be related to its poorer growth on YPD 
agar plates and not reflect a lowered resistance.  The paraquat resistance exhibited by 
these mutants was not due to increased resistance to oxidative stress in general as they 
were not hyper-resistant to hydrogen peroxide (Y. -L. Chen and T. B. Reynolds, data not 
shown). 
           The Sccho1∆ mutant has been noted to exhibit a cold-sensitive increase in petite 
formation, such that the percentage of cells that loose their mitochondrial genome 
increases as the temperature decreases (5).  As noted above, C. albicans is petite negative 
and presumably loss of the mitochondrial genome is lethal.  The cho1∆/cho1∆ mutant 
was found to be cold-sensitive for growth.  The mutant exhibited decreased growth at 
30˚C compared to 37˚C, but was completely unable to grow at 15˚C, even when the assay 
was extended out to 4 days (Fig 3-7A). The psd1∆/psd1∆ and psd1∆/psd1∆ psd2∆/psd2∆ 
mutants also exhibited cold sensitive growth, although the psd1∆/psd1∆ mutant was not 
as sensitive as the cho1∆/cho1∆ mutant. 
           A common test for mitochondrial respiratory deficiency in yeast strains has been 
use of the indicator plates containing trypan blue and eosin Y.  On these plates mutants 
lacking mitochondrial respiratory function take up the dye more readily than wild-type 
(62, 120). This assay has been shown to work in C. albicans as well (26, 62).  This assay 
was performed on the C. albicans phospholipid biosynthetic mutants, and it was found 
that all of the mutants took up the dye at greater levels than the wild-type, but there was 
an increasing defect indicated in the mutants such that the cho1∆/cho1∆ mutant appeared 
most defective, psd1∆/psd1∆ psd2∆/psd2∆ was somewhat less defective, and the 
psd1∆/psd1∆ mutant was the least defective, but was slightly more perturbed than the 
wild-type strain (Fig 3-7B).  
Defects in PE and PS biosynthesis result in cell wall defects 
            The cho1∆/cho1∆, psd1∆/psd1∆, and psd1∆/psd1∆ psd2∆/psd2∆ mutants all 
exhibit growth defects compared to the wild-type strain (Figs 3-5 and 3-8).  A PS 
synthase mutant in Schizosaccharomyes pombe (pps1∆) has been shown to exhibit slow 
growth due to cell wall defects (112).  The C. albicans phospholipid biosynthetic mutants 
were therefore tested to determine if they too exhibited slow growth due to cell wall 




like wild-type on plates containing 1M sorbitol, 0.8M NaCl, or 0.1M CaCl2 (Fig 3-8A).  
This indicated that these mutants all exhibited some form of cell wall defect. The cold-
sensitive growth described above (Fig 3-7A) was not rescued by growth in osmoremedial 
media (Y. -L. Chen and T. B. Reynolds, data not shown).  In addition, osmotic 
stabilization did not rescue the auxotrophic defects reported above (data not shown).   
            The nature of the cell wall defect was further explored by examining different 
insults that perturb the cell wall.  The cho1∆/cho1∆ mutant and the psd1∆/psd1∆ 
psd2∆/psd2∆ double mutant both showed a strong sensitivity to 0.05% SDS, which is 
thought to measure cell wall permeability (167).  The cho1∆/cho1∆ mutant was more 
defective in this assay than the psd1∆/psd1∆ psd2∆/psd2∆ mutant.  The psd1∆/psd1∆ 
mutant did not appear to be more sensitive than wild-type on YPD plates containing 
0.05% SDS (Fig 3-8B).  In contrast, all three phospholipid biosynthetic mutants exhibited 
increased resistance to caffeine compared to the wild-type strain (Fig 3-8C). None of the 
mutants were affected by calcofluor white in the media (data not shown).  Addition of the 
chitin synthase inhibitor nikkomycin Z appeared to cause a very slight defect in growth of 
the cho1∆/cho1∆ mutant, although it was hard to measure as the mutant exhibits a growth 
defect already compared to the wild-type, and the wild-type strain is also slightly 
inhibited by nikkomycin Z (see Appendix).  The cho1∆/cho1∆ mutant also exhibited a 
defect visualized by transmission electron microscopy (TEM) that was not seen in the 
psd1∆/psd1∆ psd2∆/psd2∆ double mutant or the psd1∆/psd1∆ single mutant. TEM 
revealed that the cho1∆/cho1∆ mutant had a higher percentage of cells that exhibited an 
altered distance between the plasma membrane and cell wall (Fig 3-8D), suggesting a 
defective plasma membrane or cell wall.  
The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants exhibit defects in 
filamentous growth 
            Filamentous growth is a well known virulence factor in C. albicans, and mutants 
that show severe defects in this phenotype also often exhibit altered virulence. Mutants in 
mitochondrial respiration enzymes such as Ndh51p have shown defects in filamentous 
growth (114). Therefore, filamentous growth was examined in the cho1∆/cho1∆ and 
psd1∆/psd1∆ psd2∆/psd2∆ mutants.  Strains were streaked onto plates and grown in 
conditions known to promote filamentous growth including medium 199 at pH 7.0 
(M199-7), Spider medium, and YPD+10% serum. In comparison to the wild-type, the 
cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants were poorly filamentous (Fig 3-




then the cho1∆/cho1∆ mutant exhibited greater filamentous growth (Fig 3-9B). It was 
still less filamentous than wild-type on M199-7, but it was more filamentous than wild-
type on spider and YPD+10% serum media. Filamentous growth in the psd1∆/psd1∆ 
psd2∆/psd2∆ mutant, in contrast, was not rescued by osmotic stabilization (Fig 3-9B).  
 At very early time points, the cho1∆/cho1∆ mutant was actually hyperfilamentous 
on YPD+10% serum medium compared to wild-type, even without osmotic stabilization 
(data not shown), but at later time points the colonies appeared less filamentous (Fig 3-
9A). The cho1∆/cho1∆ mutant also formed hyper-wrinkled colonies on YPD containing 
medium, both ± serum (data not shown). Neither of these effects were observed in the 
psd1∆/psd1∆ psd2∆/psd2∆ mutant (data not shown).   
 The behavior of the mutants was also examined in liquid serum.  In 100% bovine 
calf serum, it was found that the cho1∆/cho1∆ mutant exhibited slower germ tube 
formation than the wild-type, and after a few hours growth was arrested altogether (Fig 3-
9C).  The addition of extra Etn rescued filamentous growth in the cho1∆/cho1∆ mutant, 
but extra Cho had no effect (data not shown).  The psd1∆/psd1∆ and psd1∆/psd1∆ 
psd2∆/psd2∆ mutants, in contrast, exhibited nearly wild-type levels of filamentous 
growth (Fig 3-9C).   
DISCUSSIONS 
 The cho1∆/cho1∆ mutant in C. albicans is clearly avirulent in a mouse model of 
systemic candidiasis (Fig 3-3), and cannot even cause disease in a mouse 
immunocompromised with cyclophosphamide when infected with 100-fold more 
blastospores than the wild-type strain (Fig S3-1). Examination of the mouse kidneys 
quantitatively (Fig 3-3C, S3-1) and qualitatively (Figs 3-4 and S3-1) reveal that the 
cho1∆/cho1∆ mutant is eventually completely cleared from mice and causes no apparent 
tissue damage. The loss of PS synthesis plays a very important role in the loss of 
virulence, but the downstream loss of de novo PE synthesis (Fig 3-1) also causes a loss in 
virulence. This conclusion is based on the fact that a psd1∆/psd1∆ psd2∆/psd2∆ double 
mutant is extremely attenuated for virulence (Fig 3-3B). This double mutant lacks de 
novo PE biosynthesis, like the cho1∆/cho1∆ mutant, and has a very similar drop in total 
cellular PE (Table 3-1).  However, unlike cho1∆/cho1∆, the double mutant does not lack 
PS. 
 Based on our results, we propose that the cho1∆/cho1∆ and psd1∆/psd1∆ 




function, and filamentous growth that contribute to their loss of virulence. However, the 
cho1∆/cho1∆ mutant has an additional phenotype, not shared with the psd1∆/psd1∆ 
psd2∆/psd2∆ mutant, that makes it completely avirulent. This phenotype is its severe 
growth defect in the presence of Cho as the sole exogenous source for the Kennedy 
pathway (Fig 3-1).   
 We could not find the serum level of choline or ethanolamine in mice, but rat 
serum is estimated to contain ~10 µM Cho, and is higher in some other organisms (6, 
185) . We found that the cho1∆/cho1∆ mutant had a very slow doubling time of ~36 
hours in media supplemented with 10 µM Cho (Table 3-2).  Supplementing the media 
with 1 mM Cho (100 x increase) did not increase the growth rate in the early time points 
and had a modest effect only after several days (data not shown).  Rat serum also contains 
an estimated 30 µM Etn (87), however, C. albicans cho1∆/cho1∆ and psd1∆/psd1∆ 
psd2∆/psd2∆ mutants require a minimum of ~1 mM Etn to fulfill their auxotrophic 
requirements, so the level of Etn in the serum is inadequate to support growth of the 
cho1∆/cho1∆ mutant. This is reflected by the inability of the cho1∆/cho1∆ mutant to 
progress beyond initial germ tube formation in 100% serum unless supplemented with 1 
mM Etn (Fig 3-9C), and the inability to appreciably grow in liquid or solid media 
supplemented with 30 µM Etn (data not shown). We propose that the cho1∆/cho1∆ 
mutant is extremely avirulent because it is unable to grow in the host environment due to 
insufficient Etn and Cho levels.  
 The behavior of the C. albicans cho1∆/cho1∆ mutant in Etn vs Cho supplemented 
glucose media is very different from the S. cerevisiae Sccho1∆ mutant when it is grown 
on glucose media containing Etn or Cho, and is more akin to the Sccho1∆ mutant grown 
on a non-fermentable carbon source supplemented with Etn or Cho (13). On non-
fermentable carbon sources, such as lactate, the Sccho1∆ mutant is also only able to grow 
on Etn.  This is believed to be caused by the increased need for mitochondrial activity, 
which is an organelle rich in PE.  The DPL1 salvage pathway is not able to efficiently 
supply Etn for the increased demand for mitochondrial activity. In fact, overexpression of 
DPL1 rescues growth of Sccho1∆ mutants on non-fermentable carbon sources (13).  
 Based on the work from S. cerevisiae, it was expected that the lack of 
responsiveness to Cho in the C. albicans cho1∆/cho1∆ mutant was due to the lack of de 
novo PE formation and poor mitochondrial activity. If this were the case, then the 
psd1∆/psd1∆ psd2∆/psd2∆ mutant should share this phenotype as it has a similar loss of 




albicans (Fig 3-5). In fact, in this regard, C. albicans even differs from the PS synthase 
mutant pps1∆ in S. pombe, another petite negative yeast. The pps1∆ mutant is also an Etn 
auxotroph that cannot be supported by Cho even on fermentable carbon sources (112). 
However, further work with a mutant lacking all three S. pombe PS decarboxylase genes 
(psd1-3∆) has revealed that a lack of PE was the cause of the inability to respond to Cho 
(103). Thus, inability to respond to Cho due to a loss of PS in particular is specific to C. 
albicans. The reason for this defect is unknown, but several possibilities present 
themselves. 1) In the psd1∆/psd1∆ psd2∆/psd2∆ mutant there is a buildup of PS. Perhaps, 
PS can compensate for the lack of PE in the mitochondria. PS decarboxylase mutants in S. 
pombe and S. cerevisiae also experience a buildup of PS (13, 112). So if this explanation 
is correct, C. albicans is unusual. 2)  The DPL1 pathway in C. albicans may be 
compromised by a lack of PS, and this does not allow it to supply sufficient PE even on a 
fermentable carbon source. 3) PS or PE is required for the function of several transporters 
in S. cerevisiae (124, 131, 132, 146), and it is possible that the transporter for Cho in C. 
albicans is inhibited by a loss of PS in the membrane. This has not been observed for the 
Cho transporter, Hnm1p (96), in S. cerevisiae, but may be the case for the transporter in C. 
albicans. If this is the case, then cells growing on Cho alone would not be able to make 
sufficient PC via the Kennedy pathway to grow efficiently (Fig 3-1). Whatever the reason 
for the inability of Cho to supplement growth of the cho1∆/cho1∆ mutant in the presence 
of Cho alone, we believe that is an important contributor to its loss of virulence.  
Loss of de novo PE biosynthesis also contributes to a loss of virulence 
 The psd1∆/psd1∆ psd2∆/psd2∆ mutant is very attenuated for virulence. It suffers 
a growth defect compared to wild-type,  but in comparison to the fully virulent 
psd1∆/psd1∆ mutant, its growth is not seriously diminished (Fig 3-5, Table 3-2). This 
result suggests to us that the psd1∆/psd1∆ psd2∆/psd2∆ mutant is defective in virulence 
for reasons other than a slightly diminished growth rate. This mutant, like the 
cho1∆/cho1∆ mutant exhibits defects in cell wall biosynthesis, mitochondrial function, 
and hyphal growth. All of these factors might contribute to a loss of virulence and 
inability to grow in the host.   
 Three of the phospholipid mutants in this analysis, psd1∆/psd1∆, cho1∆/cho1∆, 
and psd1∆/psd1∆ psd2∆/psd2∆, all exhibited some level of cell wall defects including 
osmoremedial growth and resistance to caffeine (Fig 3-8). However, only the two 
virulence-defective mutants, cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆, exhibited a 




permeability of the cell wall (167). The cho1∆/cho1∆ mutant has a stronger defect than 
the psd1∆/psd1∆ psd2∆/psd2∆ mutant in this regard, and also exhibits an increased 
distance between the cell wall and plasma membrane in the electron micrographs that is 
not seen in the psd1∆/psd1∆ psd2∆/psd2∆ mutant (Fig 3-8D). The reason for this may be 
due to cell wall or plasma membrane defects, but is not known.   
 Both mutants suffer from a defect in de novo PE biosynthesis, which clearly 
impacts the cell wall, but loss of PS itself has an impact on this phenotype. The loss of PE 
may affect the cell wall by impacting glycosylphosphatidylinositol (GPI) anchored 
protein maturation as has been seen for the Scpsd1∆ Scpsd2∆ mutant in S. cerevisiae.  In 
the Scpsd1∆ Scpsd2∆ mutant loss of de novo PE biosynthesis leads to poor maturation of 
ScGas1p even in the presence of exogenous Etn in the media. An attempt was made to 
compare the maturation of GPI-anchored proteins in C. albicans cho1∆/cho1∆ and wild-
type strains by Western blotting using an antibody specific to ScGas1p that has been 
shown to cross-react with similar C. albicans cell wall proteins. However, the results 
were inconclusive (data not shown), and we do not know if GPI-anchor synthesis is 
impacted in C. albicans in a similar manner as in S. cerevisiae. If so, then this may help 
to explain the cell wall defects seen in the C. albicans psd1∆/psd1∆ psd2∆/psd2∆ mutant.  
 Alternatively, PE biosynthesis defects may impact virulence by affecting the 
mitochondria.  Three of the phospholipid biosynthetic mutants, psd1∆/psd1∆, 
cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆, all exhibited resistance to paraquat on 
plates (Fig 3-6A) suggesting that they have defects that affect respiration. The mutants 
also exhibited very similar resistances to paraquat quantitatively, expect for the 
psd1∆/psd1∆ psd2∆/psd2∆ mutant, but this may be due to its growth defect in non-
osmoremedial media (Fig 3-6B). The paraquat resistance could be due to uncoupling of 
oxidative phosphorylation, as an undefined C. albicans mutant that is uncoupled for 
oxidative phosphorylation was also resistant to paraquat (26).  
 There was not an obvious difference between the virulent and non-virulent 
mutants by the paraquat resistance assay, however the trypan blue/eosin Y indicator plate 
assay revealed that the less virulent cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants 
gave a much stronger phenotype than the psd1∆/psd1∆ mutant (Fig 3-7B). The basis for 
this assay is not understood, so the particular mitochondrial dysfunction that appears to 
be worse in the cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants compared to the 
psd1∆/psd1∆ mutant is not known.  




greater defect in mitochondrial genome stability.   S. cerevisiae Sccho1∆ mutants show a 
cold-sensitive increase in petite mutant formation. The psd1∆/psd1∆, cho1∆/cho1∆ and 
psd1∆/psd1∆ psd2∆/psd2∆ mutants all showed a cold-sensitive growth defect, but 
cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants showed a stronger defect than the 
psd1∆/psd1∆ mutant (Fig 3-7A). PE has been shown to be important for maintenance of 
the mitochondrial genome, and these mutants’ phenotype may reflect a general instability 
in mitochondrial proteins.   
 The defect observed in the mitochondria correlates with defects in the cell wall 
and it is possible that these phenotypes are connected.  The function of PE in maintaining 
mitochondrial function overlaps with that of another mitochondrial lipid called 
cardiolipin (CL) (56). Mutants that lack CL due to a defect in the Pgs1p enzyme in S. 
cerevisiae have been shown to have cell wall defects due to dampened cell wall integrity 
MAP kinase (CWI-MAPK) signaling (188, 189).  It is possible that the PE deficiencies 
caused by the cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants lead to defects in 
CWI-MAPK signaling.   
 The cho1∆/cho1∆ mutant is more defective for cell wall biosynthesis and 
mitochondrial function than the psd1∆/psd1∆ psd2∆/psd2∆ mutant.  The reason for the 
increasing cell wall defect in the cho1∆/cho1∆ mutant may be related to the function of 
PS in signal transduction.  PS has been shown to stimulate ScPkc1p activity through 
ScRom2p in S. cerevisiae (79). ScPkc1p is at the head of the CWI-MAPK cascade and 
influences a number of aspects of cell wall biosynthesis (93). The loss of PS in C. 
albicans may hamper Pkc1p activity and cell wall biosynthesis in this yeast. In addition, 
PS has been shown to affect calcineurin activity as well (140). Calcineurin influences the 
cell wall in bakers’ yeast and C. albicans (52, 181). Addition of 100mM CaCl2 to the 
phospholipid mutants osmostabilizes their growth (Fig 3-8A), but addition of the 
calcineurin inhibitors cyclosporine A or FK506 (66) slightly inhibits the osmoremediated 
growth of the cho1∆/cho1∆ mutant (Fig S3-3), suggesting that PS is required for full 
calcineurin activity in C. albicans.  
 The S. pombe pps1∆ PS synthase mutant also shows cell wall defects, however its 
defects are exclusively due to the loss of PS, as a mutant lacking all three PS 
decarboxylase genes (Sppsd1-3∆) does not exhibit similar cell wall defects as a pps1∆ 
mutant (103). In addition, the nature of the cell wall defects may differ as well. The C. 
albicans mutants are not sensitive to calcofluor white and show only a very slight 




mutant is very sensitive to calcofluour white which is associated with binding to chitin 
(112). Thus, the basic defects in the cell wall may be quite different in these two yeasts. 
 The cell wall defects in the psd1∆/psd1∆ psd2∆/psd2∆ mutant may help to 
explain the defects in virulence as a number of cell wall mutants have been found that are 
reduced in virulence (7, 110, 115, 119, 129, 135). One explanation for the reduced 
virulence in some cell wall mutants is increased “unmasking” of ß1,3-glucan, and greater 
immune response from the host (177, 178). This may be the case for the psd1∆/psd1∆ 
psd2∆/psd2∆ mutant, but this remains to be tested.   
 An interesting contrast to the strong virulence defect of the psd1∆/psd1∆ 
psd2∆/psd2∆ mutant is the psd1∆/psd1∆ mutant. In S. cerevisiae, the ScPsd1p enzyme is 
localized to the mitochondria and produces 90% of the de novo synthesized PE in the cell. 
The C. albicans Psd1p enzyme is likely similar since it is much more defective for 
growth in the absence of Etn supplementation. In fact, as in S. cerevisiae, the Kennedy 
pathway does not seem to be able to fully compensate in C. albicans in the absence of 
Psd1p or both enzymes (13). The psd1∆/psd1∆ mutant is fully virulent even though it 
does have cell wall and mitochondrial defects, although milder than the double mutant. 
Surprisingly, the psd1∆/psd1∆ mutant actually colonized the kidneys to a greater extent 
than the wild-type. The reason for this is not known, but it bears some resemblance to an 
undefined C. albicans oxidative phosphorylation decoupling mutant. This mutant also 
colonized the kidneys efficiently, but it was avirulent. This mutant was suggested by the 
authors to carry multiple undefined mutations, so its avirulence and heavy colonization of 
the kidneys may be unlinked (26). Thus, it is possible that the psd1∆/psd1∆ mutation’s 
mitochondrial defect may help lead to better immune evasion and colonizing of the 
kidneys. However, if this is the case, then even greater defects related to PE depletion (i.e. 
psd1∆/psd1∆ psd2∆/psd2∆ mutant) lead to a loss of virulence and colonization. These 
questions all remain to be resolved. 
Filamentous growth in the absence of PE and PS 
            The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants exhibited defects in 
filamentous growth in response to several different environmental stimuli such as pH, 
glucose starvation, and serum (Fig 3-9). Filamentous growth has been associated with 
virulence in C. albicans, and this could be a contributor to the avirulence of these strains 
as well. The cho1∆/cho1∆ mutant was arrested in germ tube formation in serum (Fig 3-
9C), but this is likely related to its growth defect in medium supplemented with Cho (Fig 




recovery of filamentous growth (data not shown). The psd1∆/psd1∆ psd2∆/psd2∆ mutant 
did not exhibit this defect in 100% serum (Fig 3-9C). It is of note that it has been shown 
that disruption of the mitochondrial electron transport chain NADH dehydrogenase 
complex I gene NDH51 leads to defects filamentous growth in basal salts medium (114). 
Thus, the filamentous growth defects in the phospholipid mutants may be related to a loss 
of mitochondrial capacity. Interestingly, the addition of 1 M sorbitol allowed a 
hyperfilamentous growth in the cho1∆/cho1∆ mutant, but not the psd1∆/psd1∆ 
psd2∆/psd2∆ mutant (Fig 3-9). The reason for this recovery in the one mutant, but not the 
other is not clear. 
Conclusions 
 The phospholipid biosynthetic mutants described in this work make it clear that 
loss of PS and de novo PE synthesis cause virulence defects. The pleiotropic nature of the 
mutants makes it difficult to determine precisely why the mutants are less virulent, but we 
believe the evidence supports the hypothesis that the loss PS leads to avirulence due to 
extremely poor growth without Etn. The loss of PE may lead to a loss of virulence more 
because of cell wall, mitochondrial, and/or filamentous growth defects. We suspect that 
all of these defects are related to mitochondrial dysfunction, but this remains to be 
determined. 
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APPENDIX C: TABLES AND FIGURES 
 
Table 3- 1. Phospholipid composition of wild type and phospholipid mutants in C. 
albicans* 
Strain Phospholipid composition (% of total)    PS     PE    PI    PC  Others 
WT  6.1 ± 0.8 
a,b,c 
 14.5 ± 0.8 
d,e,f,g 
 13.6 ± 0.9 53.6 ± 1.0 
h,i 
12.2 ± 1.7 
cho1Δ/cho1Δ  0.2 ± 0.2 a    8.7 ± 1.5 d  15.6 ± 1.8 61.0 ± 3.4 h 14.5 ± 0.5 
cho1Δ/cho1Δ::CHO1  2.8 ± 0.0 b  12.5 ± 0.3 e  15.3 ± 1.0 56.3 ± 0.9 i 13.2 ± 0.5 
psd1Δ/psd1Δ  8.0 ± 2.0  11.1 ± 0.7 f  14.4 ± 1.5 55.2 ± 2.0 11.3 ± 1.4 
psd1Δ/psd1Δ::PSD1  5.5 ± 0.2  13.8 ± 0.5  13.0 ± 0.8 56.1 ± 1.6 11.5 ± 0.6 
psd1Δ/psd1Δ 
psd2Δ/psd2Δ 11.2 ± 1.0
 c    8.0 ± 1.1 g  14.0 ± 4.8 56.4 ± 8.0 10.4 ± 1.2 
*Cultures were grown to uniform labeling in YPD medium containing 5 µCi/ml of [32P] 
phosphoric acid. Lipids were extracted and analyzed as described in Material and 
Methods. Data represent the mean ± standard deviation of one independent experiment 
and one duplicate experiment. The P values indicated by superscripted lower case were a 
























Table 3- 2. Doubling times of wild type and phospholipid mutants  
in Etn and Cho supplemented minimal media 
Strain Doubling time (hours) Etn (1mM) Cho (10µM) 
Wild-type  1.6 1.5 
cho1∆/cho1∆ 3.3          36.0 
psd1∆/psd1∆ 2.0 2.0 
































Table S3- 1. C. albicans strains 
Strain Parent Genotype Source of reference 
SC5314 
(wild-type) Clinical isolate Prototrophic wild type (55) 
YLC132 SC5314 cho1Δ::NAT1-FLP/CHO1 This study 
YLC137 YLC132 cho1Δ/CHO1 This study 
YLC142 YLC137 cho1Δ/cho1Δ::NAT1-FLP This study 
YLC334 YLC137 cho1Δ/cho1Δ::SAT1-FLP This study 
YLC337 YLC334 cho1Δ/cho1Δ This study 
YLC344 YLC337 cho1Δ/cho1Δ::CHO1-SAT1 This study 
YLC335 YLC137 cho1Δ/cho1Δ::SAT1-FLP This study 
YLC339 YLC335 cho1Δ/cho1Δ This study 
YLC345a YLC339 cho1Δ/cho1Δ::CHO1-SAT1 This study 
YLC240 SC5314 psd1Δ::SAT1-FLP/PSD1 This study 
YLC247 YLC240 psd1Δ/PSD1 This study 
YLC254 YLC247 psd1Δ/psd1Δ::SAT1-FLP This study 
YLC280 YLC254 psd1Δ/psd1Δ This study 
YLC294 YLC280 psd1Δ/psd1Δ::PSD1-SAT1 This study 
YLC243 YLC250 psd2Δ::SAT1-FLP/PSD2 This study 
YLC250 YLC243 psd2Δ/PSD2 This study 
YLC257 YLC250 psd2Δ/psd2Δ::SAT1-FLP This study 
YLC271 YLC257 psd2Δ/psd2Δ This study 
YLC290 YLC271 psd2Δ/psd2Δ::PSD2-SAT1 This study 
YLC299 YLC271 psd2Δ/psd2Δ  psd1Δ::SAT1-FLP/PSD1 This study 
YLC300 YLC299 psd2Δ/psd2Δ  psd1Δ/PSD1 This study 
YLC331b YLC300 psd2Δ/psd2Δ psd1Δ/SAT1-PMET3-PSD1 This study 
YLC373 YLC300 psd2Δ/psd2Δ psd1Δ/psd1Δ::SAT1-FLP This study 
YLC375 YLC373 psd2Δ/psd2Δ psd1Δ/psd1Δ This study 
a another separately derived cho1Δ/cho1Δ::CHO1 reintegrant strain. 











Table S3- 2. Plasmids 
Plasmids Characteristics Source of reference 
pJK863 CaNAT1-FLP cassette carrying nourseothricin resistance gene (154) 
pSFS2A SAT1 flipper carrying nourseothricin resistance gene (143) 
pYLC130 pJK863 flanked 5’ and 3’ CHO1NCR for CHO1 1st allele knock out This study 
pYLC326 pSFS2A flanked 5’ and 3’ CHO1NCR for CHO1 2nd allele knock out This study 
pYLC341 CHO1 reconstitution construct This study 
pYLC231 pSFS2A flanked 5’ and 3’ PSD1NCR for PSD1 gene knock out This study 
pYLC286 PSD1 reconstitution construct This study 
pYLC234 pSFS2A flanked 5’ and 3’ PSD2NCR for PSD2 gene knock out This study 
pYLC288 PSD2 reconstitution construct This study 
pYLC314 SAT1 marked CaMET3 promoter construct This study 







Table S3- 3. PCR primers   
Primer Use Sequence (5’  3’) 
JCO43 Disrupt CHO1 AAAAAAGGTACCCCCCCCACTGAACTTTAACCAA 
JCO44 Disrupt CHO1 AAAAAAGGGCCCGAAAAGTGGAAGAAGAGCTGA 
JCO45 Disrupt CHO1 AAAAAACCGCGGTTTTGGTATTATCAGACGCTG 
JCO46 Disrupt CHO1 AAAAAAGAGCTCTGCTGTGAAGAGAGCAAATG 
TRO369 Confirm cho1Δ GCACGTCAAGACTGTCAAGG 
JCO96 Confirm cho1Δ, psd1Δ, psd2Δ TGAAGGGGGAGATTTTCACT 
JCO99 Confirm cho1Δ AGATCATTCAAGCTACCCAG 
JCO169 Restore CHO1 AAAAAAGCTTTCTCTATGGTTTAGGAATT 
JCO141 Disrupt PSD1 AAAAAAGGGCCCTAAAGCAGCGTGGTATCGTGA 
JCO142 Disrupt PSD1 AAAAAACTCGAGCAGTCAAACAAAGGAGTAACG 
JCO143 Disrupt PSD1 AAAAAACCGCGGAGGAAGCTCAGCGTAATGGTT 
JCO144 Disrupt PSD1 AAAAAAGAGCTCCAGTTGCAGATCTTGGTGTTG 
JCO145 Confirm psd1Δ TTCAACTTGTTGGTGACCCA 
JCO157 Restore PSD1 AAAAAAGATATCCCTCTATACGAACCCACCTAA 
JCO146 Disrupt PSD2 AAAAAAGGGCCCGAGTTGTAGCAAAAGTTACCG 
JCO147 Disrupt PSD2 AAAAAACTCGAGTGCTGGGTTGAGTTGAATTCT 
JCO148 Disrupt PSD2 AAAAAACCGCGGGTCGTACATTAAGCAAATGAA 
JCO149 Disrupt PSD2 AAAAAAGAGCTCCCGATTACTTTCCTCATCGT 
JCO150 Confirm psd2Δ AGCGGGGAATCAAGTTACAA 
JCO158 Restore PSD2 AAAAAAGATATCACTTTAATCTTCACTTTTGA 
JCO165 PSD1 conditional construct AAAGAATTCCGTCAAAACTAGAGAATAATAAAG 
JCO166 PSD1 conditional construct AAAGAATTCGTTTTCTGGGGAGGGTATTT 
JCO167 PSD1 conditional construct AAACCGCGGATGCCACTCAAACCTATTTCG 










Fig 3- 1. The aminophospholipid biosynthetic pathways of both yeast and humans consist 
of two alternative pathways: 
The de novo pathway and the Kennedy pathway, but there are significant differences in 
the de novo pathways of mammals and fungi. The Kennedy pathways of the two 
organisms are similar in structure, but the level to each is used to generate particular 
phospholipids is indicated by the thickness of the arrows.  Dark bold arrow are used the 
most, dotted arrows the least, and thin solid arrows at intermediate levels.  The de novo 
pathways differ between mammals and yeast. The yeast makes PS from CDP-DAG via 
the PS synthase (Cho1p) while mammals use Pss1 or Pss2 to make PS from PC or PE, 
respectively.  Yeast carries two decarboxylases which convert PS to PE while mammals 
only carry one (PSD).  Yeast convert PE to PC via three methylation reactions that are 
performed by two different  sequential methylase enzymes whereas mammals only have 
one methylase (PEMT) that performs all three reactions.  Etn: ethanolamine, Cho: choline, 
PS: phosphatidylserine, PE: phosphatidylethanolamine, PC: phosphatidylcholine, CDP-
DAG: cytidyldiphosphate diacylglycerol, DAG: diacylglycerol, PMME: 
phosphatidylmonomethylethanolamine, PDME: phosphatidyldimethylethanolamine, Etn-
P: phosphoethanolamine, Cho-P: phosphocholine, Etn-CDP: ethanolamine-








Fig 3- 2. CHO1 is required for phosphatidylserine synthesis in C. albicans.  
(A) Structure of the CHO1 disruption construct. Approximately 500 base pairs of non-
coding DNA flanking the 5’ and 3’ ends of the CHO1 gene (5’-and 3’-CHO1NCR, 
respectively) were cloned onto either flank of the CaNAT1-FLP construct or SAT1 flipper 
(143, 154).  The SAT1 flipper regions are in parentheses. The thick dark arrows represent 
the FRT sites of the FLP recombinase. The ball and stick represents the ACT1 terminator 
(ACT1t) and the thinner arrow on a raised line represents the SAP2 promoter (PSAP2, 
CaNAT1-FLP) or MAL2 promoter (PMAL2, SAT1 flipper). (B) The CHO1-SAT1 construct 
used to reintegrate CHO1 into the cho1∆/cho1∆ mutant. (C) Southern blotting was used 
to confirm the CHO1 disruptions. (D) Separation of phospholipids from wild type and 
mutant strains. The four major phospholipids were examined in the wild-type and mutant 
strains.  Positions of the different phospholipid spots were determined by comparing them 
with the migration of phospholipid standards, which are marked to the side of 
autoradiogram. The identity of the PS band from the wild type has also been confirmed 
by mass spectrometry (see text). (E) Five-fold spot dilution assays depicting the 
sensitivity and resistance of the wild type and cho1Δ/cho1Δ mutants to papuamide B. The 


























Fig 3- 3. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ double mutants are 
compromised for virulence.  
The survival of mice following intravenous challenge with 106 C. albicans blastospores 
was monitored. The number of mice used in a specific strain is indicated in parentheses. 
(A) Mice injected with cho1∆/cho1∆ mutants exhibited avirulence (P<0.0001 as 
compared with wild type). (B) Mice injected with psd1∆/psd1∆ psd2∆/psd2∆ double 
mutants exhibited very attenuated virulence (P<0.0001 as compared with wild type). (C) 
The fungal burden in the kidneys was quantified at day 5 after infection. The error bar 









Fig 3- 4. Histological sections of kidneys dissected from mice infected with specific 
strains.  
The mice were sacrificed at day 5 after infection. Gomori Methenamine Silver (GMS) 
and Hematoxylin and Eosin (H&E) staining were used to observe C. albicans 







Fig 3- 5. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants are ethanolamine 
auxotrophs.  
(A) The cells were streaked onto Etn/Cho free medium supplemented with Etn , Cho, or 
neither, and grown for 2 days at 37°C. For the growth curves shown in B and C, log-
phase cells were diluted into Etn free medium plus 1mM Etn (B) or 10 µM Cho (C) at a 
concentration of 0.1 OD600/ml. The growth curves were measured every two hours for 8 
hr  (right hand graphs) and then once daily for 14 days (left hand graphs). The error bars 





Fig 3- 6. The phospholipid biosynthetic mutants are resistant to paraquat.  
(A) The overnight cultures were five-fold diluted and spotted onto YPD plates with or 
without 10mM paraquat. The plates were incubated for 24h at 37°C. (B) The number of 
colonies of the wild type and phospholipid biosynthetic mutant strains that could grow on 
medium containing various concentrations of paraquat (0-10mM) were counted for each 
strain and plotted. The colonies were counted after plates had been incubated at 37°C for 
1 to 2 days. The asterisk represents a P value of <0.02 when comparing mutant’s survival 
percentage to that of the wild type. The error bar represents the mean ± standard error of 







Fig 3- 7. Defects in PE and PS biosynthesis result in cold sensitivity and mitochondrial 
respiration defects.  
(A) Five fold dilutions of overnight cultures were spotted onto YPD medium and grown 
at various temperatures for the indicated amounts of time. (B) A trypan blue & eosin Y 
indicator plate was used to test for mitochondrial dysfunction. The streaked cells were 

















Fig 3- 8. Defects in PE and PS biosynthesis result in cell wall defects.  
(A) The overnight culture cells were five-fold diluted, spotted onto YPD containing 
osmotic stabilizers CaCl2, sorbitol, or NaCl, and grown for 24 h at 37°C. (B) & (C) The 
overnight culture cells were five-fold diluted and spotted onto YPD plates containing 
SDS or caffeine. (D) The overnight cultures cells were washed and diluted into YPD 
liquid medium at 0.4 OD/ml and grown at 37°C for 3h before collecting the cells for 
transmission electron microscopy observation. The cell wall thickness was quantitatively 


























Fig 3- 9. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ mutants exhibit filamentous 
growth defects. 
 Strains were streaked onto plates without (A) and with (B) 1M sorbitol and grown at 
37°C for appropriate time. (C) Overnight cultures grown at 37°C with shaking were 
washed twice and diluted into 100% serum to a concentration of 0.01 OD/ml. Cells in 
100% serum were transferred to polystyrene plastic well and incubate at 37°C for 4 hrs. 


























Fig S3- 1. The cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ double mutants are 
compromised for virulence in immunocompromised mice.  
Mice that were immunocompromised with cyclophosphamide were injected with 106 
blastospores of cho1/cho1Δ mutants, whereas mice injected with the wild type, 
psd1∆/psd1∆, or psd1∆/psd1∆ psd2∆/psd2∆ double mutant strains received 104 
blastospores.  Thus, mice received 100-fold more cho1∆/cho1∆ blastopores than 
blastospores from other strains. The survival of mice following intravenous challenge 
was monitored twice a day. The number of mice used in a specific strain is indicated in 
parantheses. (A) Mice injected with cho1∆/cho1∆ and psd1∆/psd1∆ psd2∆/psd2∆ double 
mutants exhibited avirulence and attenuated virulence, respectively. However, 
psd1∆/psd1∆ was as fully virulent as the wild-type. (B) The fungal burden in the kidneys 
was quantified from mice sacrificed at day 4. The error bars represents the mean ± 
standard deviation of three randomly selected mice infected with specific strains. (C) The 









Fig S3- 2. Southern blotting confirmed the PSD1 and PSD2 disruptions.  
The genomic DNAs were extracted from wild-type and mutants. (A) Twenty µg of DNA 
from wild type and psd1Δ/psd1Δ strains were digested by XhoI, and probed using a DNA 
fragment representing the 3’ noncoding region of the PSD1 gene. (B) Twenty µg of DNA 
from wild type and psd2Δ/psd2Δ strains were digested by BamHI, and probed using a 













Fig S3- 3. The cho1∆/cho1∆ cell wall defect appears to be in part due to perturbation of 
calcineurin.  
The overnight cultures were five-fold diluted, spotted onto YPD containing 100mM 
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           The yeast Candida albicans is a very common cause of fungal infections in 
humans and serves as a model organism to study fungal virulence. C. albicans is a 
versatile pathogen that can cause life-threatening systemic infections in 
immunocompromised patients as well as painful mucosal infections of the oral and 
vaginal surfaces. Virulence factors exhibited by C. albicans include growth at 37°C, 
dimorphism, and production of secreted hydrolases such as proteases, lipases, and 
phospholipases. The pathways that regulate the transcription of secreted aspartyl protease 
(SAP) virulence factors in C. albicans are beginning to be understood, but much remains 
to be learned. Here we report the finding that the gene OPI1 affects the virulence of C. 
albicans. Homozygous disruptants of OPI1 (opi1Δ/opi1Δ) exhibits a significant reduction 
in virulence compared to wild-type in a rat model of vaginal infection. This phenotype is 
similar to that reported for the sap2Δ/sap2Δ mutant and suggests that OPI1 may regulate 
SAP2 during vaginal infections. Conversely, the opi1Δ/opi1Δ strain does not have a 
substantial effect on virulence in a mouse model of systemic infection. Thus, OPI1 
affects virulence in a host-site specific manner. The best characterized homologue of 
OPI1 is the Saccharomyces cerevisiae gene ScOPI1, which encodes a negative regulator 
of inositol biosynthesis that acts by repressing transcription of the inositol biosynthetic 
gene INO1. We have found that in C. albicans, OPI1 does not play a role in the regulation 
of INO1. Taken together, our results describe a novel regulatory protein is required for 
establishing infection in rat vagina and illustrate that the regulation of inositol 
















            Candida albicans is a commensal organism that lives as benign resident of the 
microflora of mammalian hosts. It can shift from a commensal to a pathogenic state in 
response to environmental stimuli that trigger developmental programs that induce the 
expression of virulence factors (65). Virulence factors exhibited by C. albicans include 
growth at 37°C, dimorphism, and production of secreted hydrolases such as proteases, 
lipases, and phospholipases. The pathways that regulate the transcription of secreted 
aspartyl protease (SAP) virulence factors in C. albicans are beginning to be understood, 
but much remains to be learned. SAPs are encoded by a gene family of 10 related genes 
(SAP1 to SAP10) (123). Unlike SAP1 to SAP8, which encode secreted proteases, SAP9 
and SAP10 encode GPI-anchored proteases, located at cell membrane or cell wall, and 
both are required for virulence (1). Among this family of genes, Sap2p is the most well-
studied protease since it plays the major secreted protease during in vitro growth 
conditions, and also plays a role in pathogenesis.  
 The knowledge of SAP2 regulation is limited. SAP2 is under the control of STP1 
transcription factor and STP1’s upstream GATA transcription factors GLN3 and GAT1 (34, 
111). The importance of SAP2 in pathogenesis has been discussed by several groups. For 
instance, De Bernardis et al. demonstrated that SAP2 was the major virulence contributor 
in the rat vaginitis model (38). Schaller et al. showed that SAP2 was required to cause 
tissue damage in an in vitro model of vaginal candidiasis (149). In addition, Hube et al. 
demonstrated that SAP2 was required for virulence in a the rodent model of systemic 
infection (74). In contrast, Lermann and Morschhauser showed data contradictory to 
Schaller et al, 2003 that SAP2 was not required to invade and damage in both oral and 
vaginal reconstituted human epithelium (91).  Thus, there is controversy about the role of 
SAP2 in pathogenesis. 
            S. cerevisiae OPI1 (ScOPI1) is a negative regulator of inositol biosynthesis which 
inhibits ScINO1’s transcriptional activator ScINO2 (174, 179). In addition, it plays a role 
as a regulator of ScFLO11, an adhesion molecule, and is required for invasive growth and 
mat formation in S. cerevisiae (144). Inositol-3-phosphate synthase, encoded by ScINO1, 
catalyzes the conversion of glucose-6-phosphate to inositol-3-phosphate, which is then 
dephosphorylated by INM1 or INM2 to form inositol (24). The structural gene encoding 
ScINO1 has been demonstrated to be conserved between S. cerevisiae and C. albicans, 
and shares similar function (25, 84). C. albicans and S. cerevisiae INO1 homologs are 




orthologue in C. albicans (OPI1) can complement Scopi1Δ for INO1 regulation in S. 
cerevisiae (68). We therefore hypothesized that OPI1 might function as an INO1 negative 
regulator in C. albicans. However, a report from Hoppen et al. suggested that the 
regulation of the INO1 expression in these two yeasts might not be conserved.  The C. 
albicans heterodimeric transcription factors INO2 and INO4 (related to ScINO2 and 
ScINO4 from S. cerevisiae) did not regulate INO1, but instead activated ribosomal protein 
genes such as RPL32 (71). The results indicated that inositol regulation might be 
transcriptional rewired between these two related eukaryotic organisms. In fact, 
Martchenko et al. has demonstrated that the GAL4 transcription factor homologs appear 
rewired between these two organisms. In C. albicans the GAL4 homolog activated the 
gluconeogenesis gene LAT1 instead of galactose metabolism genes such as GAL10, and 
surprisingly GAL10 was activated by another transcription factor CPH1 (107). Therefore 
it is very interesting to investigate if OPI1 shares similar inositol regulation as ScOPI1. 
            Here we report the finding that OPI1 does not regulate inositol biosynthetic gene 
INO1 but affects the virulence of C. albicans. In addition, OPI1 affects morphogenesis at 
30ºC, and establishing infection in a rat vaginitis model. These results illustrate that the 
regulation of inositol biosynthesis in C. albicans and S. cerevisiae is different. 
MATERIALS AND METHODS 
Strains and growth media 
      C. albicans strains used in this study are shown in Table 4-1 (see all tables and 
figures in the appendix C). Media used in this study include YPD (yeast extract-peptone-
dextrose, 1% yeast extract, 2% peptone, 2% glucose), defined medium 199 (M199, 
Invitrogen, pH7.0 adjusted by 150mM HEPES), Spider (1% nutrient broth, 1% mannitol, 
0.2% dipotassium phosphate, 1.35% agar), YPD containing 10% Bovine Fetal serum, 
YCB-BSA-YE (1.17% yeast carbon base, 0.2% BSA, 0.1% yeast extract, pH 5.0). Unless 
otherwise stated, agar plates were solidified with 2% agar (granulated, Fisher). 
Strain construction 
    The C. albicans OPI1 gene (OPI1) was disrupted by using the CaNAT1-FLP 
cassette (154). For the OPI1 disruption construct, the 379 basepair (bp) 5’ non-coding 
region (NCR) of OPI1 was amplified with primers TRO522 and TRO526 (Table 4-3), 
and cloned as a KpnI-ApaI digested 228bp fragment into pJK863 5’ of the CaNAT1-FLP 
cassette (Fig 4-1A). The 448 bp 3’ NCR of OPI1 was amplified with primers TRO524 




CaNAT1-FLP cassette (Fig 4-1A). This created the OPI1 knock out construct plasmid 
pYLC36 (Table 4-2, Fig 4-1A), which was cut with KpnI and SacI to release the 
disruption construct which was transformed into the wild type SC5314 strain by 
electroporation as described previously (36, 143). The disruption construct was used to 
sequentially disrupt both alleles of OPI1 as previously described (154). The OPI1 
reconstitution construct was made by amplifying a 1.7 Kb fragment containing the OPI1 
ORF and 5’ NCR from SC5314 genomic DNA using primers (JCO12 and JCO14) that 
introduced KpnI and SalI sites. This fragment was ligated into the pRS316 vector along 
with another 1.7 Kb fragment containing the NAT1-3’OPI1NCR amplified from plasmid 
pYLC36 using primers JCO50 and TRO525 which introduced SalI and SacI sites. This 
resulted in the OPI1 reconstitution plasmid pYLC37 (Table 4-2, Fig 4-1B). The 3.4 Kb 
KpnI-SacI fragment from pYLC37 was transformed into the opi1∆/opi1∆ mutant (YLC88) 
in order to create the reconstituted opi11∆/opi1∆::OPI1 strain (YLC117). 
            The SAP2 constitutively expression construct was made by cloning dominant 
selectable marker NAT1 with primers JCO129 and JCO130 to NdeI-digested pAU34 (168) 
and resulted in pYLC219. The SAP2 ORF was then cloned to XmaI-digested pYLC219 
with primers JCO131 and JCO132, and resulted in pYLC221 which can constitutively 
express SAP2 under the control of the ACT1 promoter. To transform this constitutive 
construct to wild type and opi1∆/opi1∆ mutant, a PpuMI-digested linear plasmid 
pYLC221 was used to integrate at URA3 site of Candida genome, and resulted in 
OPI1/OPI1::pACT1::SAP2 (YLC223) and opi1∆/opi1∆:: pACT1::SAP2 (YLC226). 
Northern blot analysis 
    Northern blotting for SAP2 and INO1 expression was performed as described 
(144) with the following exceptions. Strains grown in YCB-BSA-YE at 37°C for 12 hrs 
(for SAP2) and in liquid medium 199 (pH 7.0) at 37°C for 2 hrs (for INO1) were 
collected for total RNA extraction by the hot phenol method (144). The PCR product 
containing bps 17-571 of the SAP2 ORF (primers JCO35 and JCO36) and bps 76-581 of 
the INO1 ORF (primers TRO562 and TRO563) were used as probes. Expression was 
normalized against C. albicans ACT1 gene expression probed on the same membrane. 
The ACT1 probe was generated with the primers JCO48 and JCO49. 
Southern blot analysis 
    Hybridization conditions for the Southern blot analysis were similar to those for 
Northern blot analysis, except that the Techne Hybrigene oven was set to 60°C for the 




YPD at 30°C overnight. The genomic DNA was extracted using the Winston-Hoffman 
method (70) and 20µg of genomic DNA were subjected to Southern blotting. The 
genomic DNA of opi1 mutants was cut by KpnI and SphI restriction enzymes. PCR 
products containing the ~500bp 3’ NCR of OPI1 (primers TRO524 and TRO525) was 
used as probes for Southern blot confirmation (Fig 4-1C). 
Mouse infection studies 
    Five- to six-week-old male CD1 mice (18 to 20g) from Charles River 
Laboratories were used in this study. Mice were housed at five per cage. For infection, 
colonies from each C. albicans strain were inoculated into 20ml of YPD. Cultures were 
grown overnight, washed twice with 25ml of sterile water, counted by hemacytometer, 
and resuspended at 107 cells per ml in sterile water. The cells were then plated on YPD to 
determine the viability. Mice were injected via the tail vein with 0.1ml of the cell 
suspension (106 cells), and the course of infection was monitored for up to 14 days. At 
least two independent infections were performed for each strain. Survival was monitored 
twice daily, and moribund mice were euthanized. All experimental procedures were 
carried out according to the NIH guidelines for the ethical treatment of animals. 
    The statistical analysis was done using Prism 4.0 software (GraphPad Software). 
For the mouse model of systemic infection, Kaplan-Meier survival curves were compared 
for significance using the Mantel-Haenszel log rank test. Statistical significance was set at 
P < 0.05. 
Rat vaginitis studies 
      The protocol of estrogen-dependent rat vaginal infection model adapted from De 
Bernardis F. et al (38) was used throughout this study. Briefly, oophorectomized female 
Wistar rats (80-100g; Charles River, Calco, Italy) were injected subcutaneously with 
0.5mg of estradiol benzoate (Benzatrone; Samil, Rome). Six days after the first estradiol 
treatment, the animals were inoculated intravaginally with 107 yeast cells of each C. 
albicans strain tested in 0.1mL. The inoculum was dispensed into the vaginal cavity 
through a syringe equipped with a multipurpose calibrated tip (Combitip; PBI, Milan, 
Italy). The yeast cells had been previously grown in YPD broth at 28°C on a gyratory 
shaker (200rpm), harvested by centrifugation (1500g), washed, counted in a 
hemacytometer, and suspended to the required number in saline solution. At least two 
independent experiments were done, and in each experiment, each candidal strain was 
inoculated into at least 5 rats. Kinetics of C. albicans growth in and clearance from the 




medium at 28°C for 48h. The samples were harvested by scraping the vaginal cavity of 
each animal in indicated days with a calibrated, plastic loop (1μL) (Disponoic; PBI). 
RESULTS 
OPI1, unlike ScOPI1, does not regulate INO1 in C. albicans 
Though C. albicans Opi1p has been demonstrated to repress INO1 expression in S. 
cerevisiae (68), we show that it does not play a role in inositol regulation in C. albicans. 
Both copies of the CaOPI1 gene were disrupted using the CaNAT1-FLP cassette as 
described in Fig 4-1 and the materials and methods. The wild type and opi1Δ/opi1Δ 
strains were both found to express similar amounts of INO1 mRNA in Medium 199, pH 
7.0, which contains only ~ 10 µM inositol (Fig 4-2). INO1 mRNA expression was 
repressed in the presence of 75μM inositol in both strains suggesting that inositol 
biosynthesis is regulated by different transcription factors in C. albicans.  
opi1Δ/opi1Δ mutant exhibits hyperfilamentous growth in three filament-inducing    
 media at 30ºC 
        From our previous work, we showed that ScOPI1 regulates mat formation, 
invasive growth, and ScFLO11 expression (144). We therefore hypothesized that OPI1 
would affect filamentous growth in C. albicans. Three filament-inducing media were 
used to test our hypothesis. We found that the opi1Δ/opi1Δ exhibited hyperfilamentous 
growth at 30°C on solid filament-inducing agar plates (Fig 4-3); however, these effects 
were not seen at 37°C. These phenotypes were also not seen in those filament-inducing 
liquid media at both 30°C and 37°C.  
            Since we found the OPI1 affected filamentous growth on filament-inducing solid 
agar plates, we hypothesize that this gene might affect the expression of other hyphae-
specific genes, such as HWP1 and ECE1. However, we found OPI1 is not involved in 
regulating expression of those genes (data not shown). 
OPI1 does not affect virulence in a mouse model of systemic infection 
    A gene involved in regulating C. albicans morphogenesis might play as a 
virulence factor (180). We therefore used a mouse model of systemic infection to test the 
roles of OPI1 in terms of virulence. However, we demonstrated that OPI1 did not 
contribute to the virulence in this model since opi1Δ/opi1Δ exhibited a similar survival 




OPI1 is involved in establishing infection in the rat vaginitis model  
            We then use different animal model to test the roles of OPI1 in terms of virulence. 
We demonstrated that OPI1 was involved in establishing rat vaginitis. We injected 107 
cells into the rat vaginal tract, and then recovered and count cells at specific days. The 
opi1Δ/opi1Δ was very quickly cleared by the host compared to the wild type (Fig 4-5). 
These results suggest that OPI1 plays a role in establishing infection in rat vaginal.  
OPI1 affects rat vaginal establishment through regulating SAP2 
            In order to assess whether OPI1 affects rat vaginal establishment through 
regulating SAP2, we performed an epistatis experiment in which SAP2 was constitutively 
expresed in the opi1Δ/opi1Δ mutant under the control of the ACT1 promoter. The results 
showed that opi1Δ/opi1Δ::pACT1::SAP2 mutant rescued rat vaginal establishment 
similar to wild type establishment (Fig 4-6).  
DISCUSSIONS 
            Our reports show that OPI1 affects virulence in the rat vaginitis model and may 
affect SAP2 expression in vivo because opi1Δ/opi1Δ::pACT1::SAP2 mutant can restore 
opi1Δ/opi1Δ mutant colonization. However, OPI1 did not regulate SAP2 in our in vitro 
experiment (i.e. YCB-BSA-YE medium). Interestingly, OPI1 is not involved in a mouse 
model of systemic infection, suggesting OPI1 exhibited a host-specific virulence.  
            The previous report has demonstrated that OPI1 may regulate inositol 
biosynthesis and act as the negative regulator of INO1 (68). Our results show that OPI1 
does not regulate inositol biosynthesis or INO1. This difference may be due to the fact 
that in the previous report the C. albicans OPI1 was only studied when expressed 
heterologously in S. cerevisiae.  The fact that it could complement the Scopi1Δ mutant’s 
defect in repressing ScINO1 (ICRE-regulated reporter gene) expression was taken as 
evidence it did the same thing in C. albicans (68).  
 CaOpi1p may work in S. cerevisiae because it can interact with the ScIno2p and 
ScIno4p heterodimer to repress ScINO1 expression. CaOPI1 did not regulate INO1 in C. 
albicans indicating that different transcriptional regulators control INO1 in this pathogen. 
  We screened C. albicans transcription factor mutant library (provided by Aaron 
Mitchell and Dominique Slangard) to isolate INO1 regulator. However, we did not find 
any candidate in these mutant libraries. It will be interesting to identify what are the 
transcriptional activators of INO1 in C. albicans. 




mutant exhibited hyperfilamentous growth in three filament-inducing agar plates 
including medium 199, spider, and 10% serum at 30ºC. The result indicated that OPI1 
might be a temperature regulator of filamentous growth.  Csank et al. demonstrated that C. 
albicans CPP1, a tyrosine phosphatase, is required for repressing the yeast to hyphal 
transition at 23ºC in contact with solid surfaces (32, 71). The cpp1Δ/cpp1Δ mutant 
exhibited hyperfilamentous and invasive growth on spider and wide variety of rich and 
defined solid media including Lee’s medium, YPD, YPM, and 10% serum at 23ºC, but 
not at 37ºC. The germ tube formation of cpp1Δ/cpp1Δ mutant was not observed at liquid 
culture at 37ºC, an effect similar to opi1Δ/opi1Δ mutant. In contrary to opi1Δ/opi1Δ, the 
cpp1Δ/cpp1Δ mutant exhibited reduced virulence/pathogenecity in mouse systemic 
infection and mouse mastitis model (32, 61).  It is possible that Cpp1p and Opi1p may 
interact in some way.  
 In the future, it will be tested if OPI1 regulates rat vaginitis through affecting 
SAP2 expression in vivo using qRT-PCR to assay mRNA from collected rat vaginal fluid 
infected with C. albicans wild-type and mutant strains. Taken together, our data 
suggested that C. albicans has a transcriptionally rewired regulator OPI1 which does not 





















APPENDIX D: TABLES AND FIGURES 
 
Table 4- 1. C. albicans strains 
Strain Parent Genotype Source of reference 
SC5314  
(wild-type) Clinical isolate Prototrophic wild type (55) 
YLC58 SC5314 opi1Δ::NAT1-FLP/OPI1 This study 
YLC85 YLC58 opi1Δ/OPI1 This study 
YLC86 YLC85 opi1Δ/opi1Δ::NAT1-FLP This study 
YLC88 YLC86 opi1Δ/opi1Δ This study 
YLC117 YLC88 opi1Δ/opi1Δ::OPI1 This study 
SAP2MS4A SC5314 sap2Δ/sap2Δ (159) 
YLC223 SC5314 OPI1/OPI1::PACT1::SAP2 This study 


























Table 4- 2. Plasmids 
Plasmids Characteristics Source of reference 
pJK863 CaNAT1-FLP cassette carrying nourseothricin resistance gene (154) 
pYLC36 pJK863 flanked 5’ and 3’ OPI1NCR for OPI1 gene knock out This study 
pYLC37 OPI1 reconstitution construct This study 
pAU34 Constitutively expression construct under the control of ACT1 promoter (168) 
pYLC219 pAU34 contained NAT1 selectable marker This study 

































Table 4- 3. PCR primers 
Primer Use Sequence (5’  3’) 
JCO522 Disrupt OPI1 AAAAAAGGGCCCTACACACACACACACTTACACACAT 
JCO526 Disrupt OPI1 AAAAAAGGGCCCCGGTTTCCCCCTTTTTATATA 
JCO524 Disrupt OPI1 AAAAAACCGCGGTGAGTGGTGGTTTCTTTTTGTT 
JCO525 Disrupt OPI1 AAAAAAGAGCTCCAAGTTGGACTACAAATGGTCAAG 
JCO12 Restore OPI1 GTGTGGTACCTATTTCCAAATTCA 
JCO14 Restore OPI1 AAAAGTCGACCTACTACACACTACCATCTA 
TRO369a Confirm OPI1 disruptions GCACGTCAAGACTGTCAAGG 
TRO532 Confirm OPI1 disruptions ACGGCATGCTAGGTATATACTGCT 
JCO48 ACT1 Northern blot probe CCAGCTTTCTACGTTTCC 
JCO49 ACT1 Northern blot probe CTGTAACCACGTTCAGAC 
JCO35 SAP2 Northern blot probe TTCATTGCTCTTGCTATTGCT  
JCO36 SAP2 Northern blot probe CACCGGCTTCATTGGTTTTA 
TRO562 INO1 Northern blot probe GAAAACTCTGTTGTTGAAAAAGATG 
TRO563 INO1 Northern blot probe TTGTTGGCACGTTCACTTTG 
JCO129 SAP2 constitutive expression AAAAAACATATGCCCCGCGGGATATCAAGC 
JCO130 SAP2 constitutive expression AAAAAACATATGTGGGTACCGAATTCGAGCT 
JCO131 SAP2 constitutive expression AAAAAACCCGGGATGTTTTTAAAGAATATTTTC 
JCO132 SAP2 constitutive expression AAAAAACCCGGGTTAGGTCAAGGCAGAAATAC 
JCO133 SAP2 constitutive expression AGAGAGCAGAAACTCATGCCT 
JCO134 SAP2 constitutive expression TAAGCATTCCAACCAGCATC 
JCO122 SAP2 constitutive expression AAAAAAGGTACCCGTCAAAACTAGAGAATAATAAAG 
a TRO369 hybridizes to the TEF promoter in the NAT1 cassettes and served as a reverse primer in 








































Fig 4- 1. The OPI1 gene was disrupted in the strain SC5314 using the CaNAT1-
FLP cassette . 
(A) Structure of the CaNAT1-FLP-OPI1 disruption construct. Approximately 500 
base pairs of  non-coding DNA flanking the 5’ and 3’ ends of the OPI1 gene (5’-
and 3’-NCR, respectively)  were cloned onto either flank of the CaNAT1-FLP 
cassette. The thick dark arrows represent the FRT sites of the FLP recombinase. 
The ball-and-stick symbol represents the ACT1 terminator (ACT1t), and the 
thinner arrow on a raised line represents the SAP2 promoter (PSAP2). (B)  The 
OPI1-NAT1 construct used to reintegrate OPI1 into the opi1∆/∆ mutant.  (C) 
Southern blotting was used to confirm the opi1∆/∆ disruptions. Lanes: 1, wild 
type; 2, opi1∆ ::NAT1-FLP/OPI1 strain; 3, opi1∆/OPI1 strain; 4, 































Fig 4- 2. The opi1Δ/opi1Δ mutant does not regulate INO1 expression.  
Strains were grown for 2 hrs in Medium 199, pH7.0 (± 75 µM inositol) at 37°C, 
collected, and subjected to Northern blotting against INO1. ACT1 was reprobed 


























Fig 4- 3. OPI1 -/- mutants exhibited hyperfilamentous growth in filament-
inducing conditions on agar plates. 
 C. albicans strains from overnight cultures were diluted in sterile water and 







































Fig 4- 4. OPI1 is not required for virulence of C. albicans in a mouse model of 
systemic candidiasis.  
Each strain was used to infect mice by injecting 106 C. albicans yeast-form cells into 
the tail-vein of each mouse. The mice were then assessed for viability over the course 







































Fig 4- 5. OPI1 is involved in establishing infection in the rat vaginitis model.  
For each strain 5 rats were inoculated on day 0 with 107 blastospores, and 







































Fig 4- 6. OPI1 affects rat vaginal establishment through regulating SAP2.  
For each strain 5 rats were inoculated on day 0 with 107 blastospores, and vaginal cfu 







































  This thesis revolves around the roles of phospholipid biosynthetic pathways in C. 
albicans virulence. Currently, many studies have been concentrated on phospholipids 
because they play critical roles in growth, signal transduction, and virulence in addition 
to structure components. Our primary goal is to identify genes involved in these pathways 
that are required for virulence. The identification of genes involved in virulence may 
provide potential drug targets if there is no similar gene in mammalian cells. As 
mentioned in chapter 1, the five classes of antifungal drugs currently available have their 
own drawbacks such as kidney toxicity and fungal resistance. A new drug could offer an 
alternative new therapy to this opportunistic pathogen. Moreover, a new drug could be 
given in combination with the other drugs to treat systemic candidiasis even more 
efficiently (78).  
            Three related projects come together to investigate phospholipid metabolism 
genes and how they are involved in C. albicans virulence. 1)  We have found that unlike 
some other pathogens, C.albicans is able to use de novo inositol biosynthesis (INO1) or 
import of exogenous inositol (ITR1) with equal efficiency to allow virulence. This is 
presumably because either mechanism allows effective synthesis of phosphatidylinositol. 
2) The PS synthase gene CHO1 is essential for virulence in mouse model of systemic 
candidiasis, as well as cell wall integrity, and mitochondrial function. 3)  A putative 
regulator of phospholipid metabolism, OPI1, is required for morphogenesis and for 
colonization of the vaginal tract in a rat vaginitis model (see Chapter 4). Among the genes 
examined in this thesis,  CHO1 (phosphatidylserine synthase) is the most promising 
candidate for a drug target because there is no similar mammalian gene and this gene is 
conserved in opportunistic fungal pathogens including Cryptococcus, Aspergillus, and 
non-albican Candida species suggesting a drug with broad spectrum could be developed.   
           In addition to investigating the virulence,  the bacterial pathogen M. tuberculosis 
and the parasitic pathogen T. brucei, which both must make inositol de novo in order to 
cause disease or even grow, respectively (25, 109, 118). The results showed that inositol 
biosynthesis and acquisition in C. albicans is conserved with S. cerevisiae. Interestingly, 
the putative inositol regulator OPI1 gene is not conserved with ScOPI1 because OPI1 
gene did not regulate expression of the inositol biosynthesis gene INO1 in C. albicans 
suggesting inositol regulation between S. cerevisiae and C. albicans has been rewired 
(see Chapter 4). This phenomenon is also observed in Yarrowia lipolytica. Hirakawa et al. 
demonstrated that Yas3p, an opi1-family transcription factor does not regulate expression 




Taken together, the structural INO1 gene is conserved among fungi, and even other 
eukaryotes and prokaryotes, but the regulation of the INO1 gene in fungal species has 
diverged. 
            Overall, the thesis suggests that Opi1p and Cho1p could be potential drug targets, 
but Cho1p seems to be more promising because cho1Δ/cho1Δ mutants are completely 
avirulent and eventually cleared by the host (see Chapter 3). Moreover, Cho1p represents 
a new class of targets (phospholipid) for antifungal agents. The more choices of drugs the 
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APPENDIX E: SUPPLEMENTARY DATA 
 
Table E-1. All C. albicans strains*
 












Ca genes WT Hetero-1 Hetero-2 Homo-1 Homo-2 Restored Conditional SAP2 Constitutive
(+/+) (+/-:NAT1) (+/-) (-/-:NAT1) (-/-) (-/-:OPI1) 223 (from 57)
57 58 85 86 88 117 226 (from 88)
(+/+) (+/-:NAT1) (+/-) (-/-:NAT1) (-/-) (-/-:INO1)
57 100 105 111 113 120
57 101 108 126
(+/+) (+/-:NAT1) (+/-) (-/-:NAT1) (-/-:CHO1, MPAr)
57 132 137 142 172 (partial)
57 131 135 140 168 (partial)
57 131 135 191
(-/-:SAT1) (-/-::CHO1-SAT1)
57 132 137 334 337 344
(+/+) (+/-:SAT1) (+/-) (-/-:SAT1) (-/-) (-/-:ITR2)
57 176 185 192 196 211
57 179 193 199 201
INO1-/-
ITR2-/MET3::ITR2
113 180 184 261
113 181 187 266
PSD1 (+/+) (+/-:SAT1) (+/-) (-/-:SAT1) (-/-) (-/-:PSD1)
57 240 247 254 280 294
PSD2 (+/+) (+/-:SAT1) (+/-) (-/-:SAT1) (-/-) (-/-:PSD1)
57 243 250 257 271 290
PSD2 -/-
PSD1 -/MET3::PSD1
271 299 300 373 375 331
(+/+) (+/-:NAT1) (+/-) (-/-:NAT1) (-/-) (-/-:OPI3)























PSD2 -/-        
PSD1 +/-::SAT1











Fig E-1. The OPI3 gene was disrupted in the strain SC5314 using the SAT1 flipper.  
(A) Structure of knock out construct. Approximately 500 base pairs of non-coding DNA 
flanking the 5’ and 3’ ends of the OPI3 gene (5’-and 3’-NCR, respectively) were cloned 
onto either flank of SAT1 flipper. The thick dark arrows represent the FRT sites of the 
FLP recombinase. The ball-and-stick symbol represents the ACT1 terminator (ACT1t), 
and the thinner arrow on a raised line represents the MAL2 promoter (PMAL2). (B) The 
restored construct used to reintegrate OPI3 into the opi3∆/opi3∆ mutant. (C) Southern 
blotting was used to confirm the opi3∆/opi3∆ mutant. (D) opi3∆/opi3∆ mutant did not 










Fig E-2. The CHO2 gene was disrupted in the strain SC5314 using the SAT1 flipper.  
(A) Structure of knock out construct. Approximately 500 base pairs of non-coding DNA 
flanking the 5’ and 3’ ends of the CHO2 gene (5’-and 3’-NCR, respectively) were cloned 
onto either flank of SAT1 flipper. The thick dark arrows represent the FRT sites of the 
FLP recombinase. The ball-and-stick symbol represents the ACT1 terminator (ACT1t), 
and the thinner arrow on a raised line represents the MAL2 promoter (PMAL2). (B) The 
CHO2 conditional expression construct which was used to replace second wild-type 











Fig E-3. The VPS27, EFG1, CNA1, CNB1, and DPL1 knock out constructs.  































Fig E-5. The NAT1-marked construct of constitutive expression under the control of 
ACT1 promoter.  
The linear plasmids cut by PpuMI or BlpI were transformed and integrated into CaURA3 
















Fig E-6.The constitutively expression construct of SAP2.  
(A) Diagram. (B) Southern blot. The genomic DNA was digested by EcoRV (arrow) and 
5’ noncoding region of URA3 was amplified as probe ( asterisk). The strain number 57, 































Fig E-7. The cho1∆/cho1∆ mutant formed hyper-wrinkled colonies on YPD containing 
medium, both ± serum at 37ºC.  
Neither of these effects were observed in the psd1∆/psd1∆ and psd1∆/psd1∆ 

























Fig E-8. The length of mitochondria in cho1∆/cho1∆ mutant might be shorted.  
Strains were stained with the vital dye Mitotracker Red CMXRos® after growth to log 



















































Fig E-9. The phospholipid mutants were slightly susceptable to chitin synthase inhibitor, 
nikkomycin Z.  




































Fig E-10. Hydrogen peroxide has no observable effects on phospholipid mutants. 




































Fig E-11. Cell wall perturbating regagents Calcofluor white, CongoHydrogen, and drug 
Hygromycin B have no observable effects on the growth of phospholipid mutants.   


































Fig E-12. 10mM NaCN (inhibiting cytochrome aa3) seems rescue the growth of 
phospholipid mutants.  
However, SHAM (inhibiting alternative electron transport chain) has no observable 
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Fig E-13. Amphotericin B has no observable effects on the growth of phospholipid 
mutants.   

































Fig E-14. Antifungal fluconazole has no effects on the growth of cho1Δ/cho1Δ mutant.   






















Fig E-15. The constitutively expression of  C. albicans MKC1, HOG1, and CNB1 
signaling pathways.  
These pathways cannot rescue the growth of  mutants’ growth on YPD  or YPD 
containing sorbitol (data not shown). might not involve in regulating the growth of 





































Fig E-16. Phosphatidylserine (PS) can not rescue the growth of cho1Δ/cho1Δ mutant in 
our tested condition. 
 Strains with same concentration were grown overnight in indicated concentration of Etn 



























Fig E-17. C. albicans Gas1p might be affected in cho1Δ/cho1Δ mutant.  
 The intensity of Western blot results was normalized by Pma1p.  Strains were grown to 



























Top    105    146        167      100 %
Mid    100     310        220     190 %
Bot 100      230       190     290 %
P27 P100







Fig E-18. The OPI1 gene affects the transcription of the SAP2 secreted aspartyl protease. 
 Cells were grown in yeast carbon base (YCB) medium where protein (bovine serum 
albumin, BSA) was the only nitrogen source (YCB-BSA) for 12 hours at 37˚C. Total 
RNA was isolated, Northern blotted, and probed for the SAP2 gene. Expression levels 
were normalized to the ACT1 gene. Note that he old northern blot included serial opi1Δ 



























Fig E-19. OPI1 -/- mutant exhibits hyper-protease activity in YCB-BSA plate.  
(A) Plate assay. (B)  quantitative measurement of zones, and western blot results in liquid 
YCB-BSA (collected supernatant with anti-sap2p). Asterisks indicate P value as 




























1. SC+2% glucose (dextrose) 
10X YNB 25ml 
         (1) add 16.75g yeast nitrogen base w/o amino acids 
         (2) add water to 250ml, then filter sterilize and store at 4ºC  
10X Yeast Synthetic drop-out medium supplement w/o uracil 25ml 
         (1) add 4.8g Yeast synthetic drop-out medium supplement w/o uracil 
         (2) add water to 250ml, then filter sterilize  
10X uracil 25 ml (or uridine for C. albicans) 
         (1) add 50mg uracil 
         (2) add water to 250ml, then filter sterilize  
40% glucose 12.5ml  
Add water to 250ml 
 
SC: Synthetic Complete (YNB + all amino acids) 
SD: Synthetic Dextrose (YNB + Dextrose) 
 
2. YCB-BSA-YE (Yeast Carbon Base-Bovine Serum Albumin-Yeast Extract) 
2.9g     YCB 
0.5g      BSA (avoid autoclave; add from filter sterilized 10% BSA stock) 
0.25g    YE 
Add wáter to 200ml  adjust pH  bring water to 250ml. 
 
3. YCB-BSA protease halo (plate) assay 
5.8g     YCB (Bacto) 
10g      Agar (Bacto) 






4. RPMI 1640 for Fluconazole E test strips 
5.2g       RPMI 1640 (powder, Cat#50-020-PB,e Cell Gro, w/ L-Glutamine, Phenol Red,   
                                                                                           w/out NaHCO3) 
17.25g   MOPS (0.165mole/L) 
9.0g       glucose (note that 1g has already in the powder) 
7.5 g      Agar (Bacto) (1.5%)  
Add water to 450ml  adjust pH from ~5.6 to pH7.0  add water to 500ml 
 
5. M199 medium (pH7.0) 
425ml original M199 (9.5g M199, GIBCO Cat#31100-027, Invitrogen,1 pack in 1L water) 
75ml   1M HEPES (pH7.0) (150mM HEPES final) 
Auto clave. 
For making a solid plate, add 10g agar. Note that solid plate (pH4.0) cannot be solidified. 
    1M HEPES (MW=238.3): add 47.6g of HEPES into 200ml water  adjust pH 
 
6. Spider (Haoping Liu, Science) 
5g         Nutrient broth 
5g         D-Mannitol 
1g         K2HPO4 
6.75g    Agar (if solid) 
Add water to 500ml 
 
7. YPD containing 15% glycerol (for stock in -80ºC) 
1g      Yeast Extract (1%) 
2g      Peptone (2%) 
2g      Dextrose (2%) 
Add water to 70ml  add 30ml of 50% glycerol   autoclave 
 
8. Calcofluor White stock (10mg/ml stock) 
Add 100mg of Calcofluor White (M2R) to 10ml water 
Add 3µl of 10M NaOH to dissolve the powder completely 






9. Amphotericin B (10mg/ml stock) 
5mg Amphotericin B in 0.5ml DMSO 
 
10. Frequent working concentration in  testing C. albicans 
Calcofluor White (CFW, 10µg/ml); Congo Red (10µg/ml); Nikkomycin Z (10µg/ml) 
Hygromycin B (100µg/ml); Amphotericin B (10µg/ml); Cyclosporin A (100µg/ml); 
FK506 (1µg/ml); Fluconazole (100µg/ml); Ketaconazole (50µg/ml); Caffeine (10mM); 
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